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ABSTRACT 
Understanding the basic structure-function relationships that guide the biology of various 
pathogenic viruses is the cornerstone in the development of antiviral therapies. One group of 
highly pathogenic viruses, which desperately needs novel antiviral therapies, are Negative Strand 
RNA viruses. This group of viruses contains some of the most highly pathogenic and pandemic 
viruses known: like Ebola, Influenza, Marburg, and Rabies viruses. Between 2013 and 2016, 
during the latest endemic outbreak of Ebola, the World Health Organization estimated that it 
caused over 11,000 deaths. However, without in-depth understanding of the basic science that 
guides the replication of these viruses, design of targeted therapies is hard. Utilizing the model 
virus for Negative Strand RNA viruses, Vesicular Stomatitis virus, this work studies the 
structure-function relationships of the nucleocapsid protein. Since the nucleocapsid encapsulates 
the virus’ genomic material this protein is increasingly important study. Furthermore, the virus 
cannot undergo replication if the polymerase does not recognize the nucleocapsid for viral RNA 
synthesis. This work takes a three-pronged approach when investigating the nucleocapsid: 
development of a novel antiviral to target the nucleocapsid, the use of structural information to 
study the possible interactions between the nucleocapsid and the polymerase, and a study of the 
genomic constraints placed on polymerase activity by the nucleocapsid. Utilizing an already 
characterized class of compounds, polyamides, we showed that it is possible to target the 
genomic RNA in the nucleocapsid of a Negative Strand RNA virus and inhibit viral replication. 
This is the first known instance of this occurring in Negative Strand RNA viruses. To examine 
the structural interactions between the nucleocapsid and the polymerase a flexible loop was 
hypothesized to be integral toward the formation of an active polymerase complex. Alanine 
scanning deletions yielded an abolishment in polymerase activity, which could be restored after 
compensatory mutations were allowed to occur. Finally, the nucleotide content sequestered 
within the nucleocapsid has a direct effect on the processivity of the polymerase complex, and 
ushers in a paradigm changing model for how one examines Negative Strand RNA virus activity 
and the evolutionary constraints placed on the genomic RNA. Merging the findings of these 
studies together, understanding the structure-function relationships of the nucleocapsid can yield 
a lot of knowledge about the viral life-cycle of the entire Negative Stranded RNA virus family.  
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1 GENERAL INTRODUCTION: WHY STUDY VIRUSES?  
In biology, viruses represent an intellectual duality: they are so incredibly simple, but also so 
frustratingly mysterious. They have often perplexed Nobel prize winning researchers, while only 
containing the basic biological building blocks to replicate. These parasitic molecular machines 
are so vast in their diversity and display a dizzying array of functionality by infecting every 
living thing on the planet (1). Meanwhile, they simultaneously lack basic biological functions 
like a metabolism and ability to replicate outside of a host. It is through the study of this 
“contagium vivum fluidum” (contagious living fluid) (1, 2) that a relatively new scientific field 
has emerged, Virology. Virology has made huge strides in understanding and controlling 
pandemic pathogens, but at other times has completely reinvented scientific dogma. It is in the 
spirit of exploration and human ingenuity that makes this field of study so patently interesting to 
study. 
1.1 General History of Virology  
From their initial discovery in 1892 by Russian scientist Dmitri Ivanofsky until modern 
day, viruses represent a biological enigma (1, 3). In the late 19th century, the prevailing theory of 
infection was already well established by the works of Koch, Lister, and Pasteur. Koch’s 
postulates clearly outline a model for microscopic bacterial infection (1):  
(a) The organism must be regularly found on the lesions of the disease. 
 (b) The organism must be isolated in pure culture.  
(c) Inoculation of the pure organism into the host should initiate the disease.  
(d) The organism must then be recovered once again from the lesions of the host.  
At this time, this would have been considered scientific dogma. However, things changed 
with the invention of the Chamberland filter. Invented by Charles Chamberland, a colleague of 
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Pasteur, the Chamberland filter was a revolutionary porcelain filter with pores small enough to 
filter out bacterial agents. It was during this time that Dmitri Ivanofsky was working on a disease 
that was ravaging the Russian tobacco crop (2, 3). He isolated the sap from the infected plant, 
which would normally be able to infect another plant, and passed it through a Chamberland 
filter.  He hypothesized that the small pores in the filter would remove the infectious agent. 
However, this was not the case. The filtered material could still infect a healthy plant. Ivanofsky 
reported this information to the National Academy of Sciences, but the scientific understanding 
of the time did not allow him to make any overly zealous claims.  
It was not until a couple of years later that Martinus Beijerink unknowingly and 
independently verified the work of Ivanofsky (in 1898) by repeating the same experiment (4). 
However, Beijerink carried Ivanofsky’s work one step further: he showed that a serial dilution of 
the filtered sap material, could regain its potency after replication in the host. He later found that 
the agent could not be isolated and cultured, violating Koch’s principles, but needed the living 
cells or tissue to be able to reproduce (4). This kicked off a period of scientific debate into the 
nature of this infectious liquid. Was it a toxin? An enzyme? Or a particle too small to be seen by 
a light microscope? It was during this time, that the literature started to identify numerous 
accounts of these “filterable infectious agents” which violated Koch’s postulates and produced 
an amalgam of diseases (5-9). They started to call them viruses, taken from Latin meaning 
“slimy liquid or poison”(9). 
The identity of the filterable infectious liquid, was finally settled with the invention of the 
electron microscope in 1937 when the first electron micrographs were taken of the 
communicable sap and small rod-like particles were identified. This was to become the first 
image of a virus, in this case the identification of Tobacco Mosaic Virus (6). It was this ground-
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breaking technique, along with the development of the plaque assay in 1917 (5), which kicked 
off modern Virology as we know it today. 
Since their discovery, viruses have represented significant scientific paradoxes being both 
alive and not alive, being eloquently simple and frustratingly complex, and capable of massive 
death on the microbiological and macrobiological scale. It is only through the understanding of 
the basic biological driving forces behind these primitive parasites that scientists can begin to 
unwind these oxymora and usher in a new age of scientific enlightenment and human health. 
With the constant threat of emergent pandemic diseases threatening human civilization, it is of 
vital importance to thoroughly study and understand these perplexing biological materials. As 
Sun Tzu said in the Art of War, “If you know the enemy and know yourself, you need not fear 
the result of a hundred battles. If you know yourself but not the enemy, for every victory gained 
you will also suffer a defeat. If you know neither the enemy nor yourself, you will succumb in 
every battle.” This is why we study viruses.     
1.2 Viral Evolution, Classification System, and Antiviral Therapies  
To fully appreciate the scope of this dissertation, it is important to have a competent 
understanding of some basic principles of virology. These basic principles, serve as a signpost to 
constantly compare and validate our exploration of the cutting edge basic science in the context 
of the established scientific principles. The principles of viral evolution, classification, and 
discovery of antiviral therapies are directly applied throughout this dissertation. This section 
explores these basic principles to establish an understanding and common linguistic framework 
as applied to the research in this dissertation. 
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1.2.1 Viral Evolution 
Viruses represent a biological conundrum. This mystery is exacerbated when examining 
the evolution of viruses. Since viruses lack some of the basic machinery to be called a “living” 
organism, there are several evolutionary theories which pervade the scientific literature. Were 
viruses the first form of life, arising from RNA and eventually becoming more complex? Or did 
viruses co-evolve with the evolution of cells and bacteria, enacting out their parasitic existence 
from the start? Or perhaps they are a byproduct of ancient genetic material that escaped the cell, 
still needing it for replication? These are all valid hypotheses and are actively being studied and 
discussed. If one can understand viral evolution, then perhaps this knowledge can be used to 
predict novel pathogenic viruses arising from extraneous sources. Furthermore, with the vast 
amount of genomic data currently available, these predictive abilities will only continue to get 
better. Very much like evolution is at the heart of biology, the application of evolutionary 
principles is also at the heart of virology. It is the guiding force which informs all biological 
function. 
The first theory of interest is the “virus first” hypothesis. As this hypothesis suggests, 
viruses, particularly RNA viruses, predated cellular existence (10-12). This theory postulates that 
there was a pre-cellular world which belonged to a batch of ancient viruses. It was these ancient 
viruses that evolved and developed the molecular tools needed for cells to function. This theory 
is supported by the fact that viral genomes and proteins are often vastly different from their 
cellular counterparts. These sequence specific viral genes, do not share homologous proteins in 
other living materials. This hypothesis infers that before cells arose, there was a primordial 
genetically diverse pool in which freely intermixing components were assembled. This 
primordial pool eventually gave rise to modern cells and modern viruses, but the essential 
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building blocks arose from here (12). While this hypothesis states that the modern parasitic 
activity later evolved once cells took hold, a large gap in the evolutionary understanding remains. 
Also, all viruses need a cell to replicate. While it does not disprove of this hypothesis, the 
common ancestor between cells and viruses could be the same, due to this reason this hypothesis 
has been succinctly challenged and further critiqued (13). 
Another way that viruses could have arose is from a co-evolution with cells. This is 
called the “reduction hypothesis”. Much like the “virus first hypothesis”, this premise suggests 
that there was a pre-cellular world and viruses co-evolved alongside cells (10, 14). This co-
evolution means that viruses are just reduced parasites, ranging from very simple, like RNA 
viruses, to vastly complex, like some double stranded DNA viruses. As cells got more advanced, 
the viruses were able to evolve along with cells becoming more advanced themselves. This 
hypothesis has recently garnered more attention with the discovery of the very large 
mimiviruses, megaviruses, and most recently the Pandoravirus (15-17). These viruses are giant 
with the genome of Pandoravirus containing around 2.5 million bases and encoding for 2,500 
genes. The viruses share many features with other parasitic bacteria, and have added clout to this 
hypothesis of viral evolution (17). Furthermore, with the discovery of these viruses it has sparked 
the discussion to add viruses as the fourth domain of life (18). Due to their enormous complexity 
it could be hard to see how these viruses, are not something that should be seriously considered 
as a life-form. However, the presence of these viruses can also lend credence to the next 
hypothesis of viral evolution. 
The third hypothesis of viral evolution is called the “escape hypothesis” (11, 13). This 
hypothesis proposes that viruses are a part of the host cell. The genetic material surrounding viral 
functions, somehow escapes from the host cell. However, for replication of the genetic material 
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to take place, it then needs to return to the host cell. These “viruses”, or “viroids”, then can 
further evolve gain of function through horizontal gene transfer. Horizontal gene transfer occurs 
when one organism, in this case a virus, steals a gene from the host cell which then becomes 
ingrained into the viral replication cycle (19, 20). While this is most certainly has occurred, it 
again runs into a similar problem as the “virus first” hypothesis: How does one explain that the 
vast majority of viruses are non-homologous to cellular organisms (10, 13, 21)?  
While a version of every hypothesis carries a kernel of truth, the origins of viruses and 
their evolutionary path most-likely lies somewhere between all these hypotheses. One interesting 
concept, which would link all life together and viral evolution, is the concept of the virocell (10, 
12, 22, 23). The virocell is a cell that has been infected by a virus and its whole purpose is to 
produce virions. In the context of a cell, the virus is “alive” and replication starts to occur, 
effectively turning the infected cell into an entire new type of organism. This concept places the 
evolution of viruses just after the evolution of the ribosome and proteins, but before the last 
common ancestor of the modern cell. Viewing viruses from this lens is interesting because 
viruses are then “alive” during the intracellular phase of the life cycle (23). While this is still 
surely up for debate, viewing the virus in the context of a ribosome, is an interesting intellectual 
take on viral evolution. 
While viral evolution is a widely debated topic, studying viral evolution is important to 
understand both the mechanisms of viral replication and how these viruses will continue to 
change with time. Additionally, in investigating the origins of life, viruses have played a large 
role in unlocking many mysteries surrounding seemingly intractable problems. Until now, the 
diversity of the viral population has not been discussed, and understanding the basic 
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classification system, which is an evolutionarily driven discussion, is the topic of the next 
section. 
1.2.2 Viral Classification System 
In trying to better understand viruses, scientists have come up with ways to classify them. 
Being so diverse, with a wide range of hosts, symmetries, and methods of replication, viral 
classification has proved to be an interesting problem for a long time. Initially, virologists were 
classifying viruses by the nature of the disease and the host that the virus infected (24). However, 
this turned out to be a problem for a number of reasons: a plethora of viruses could cause similar 
symptoms to appear throughout the course of a disease, making classification extremely difficult; 
the structure of different virions can be radically different, but still infect the same host while 
possibly causing similar symptoms; and the molecular material which the virus uses to replicate 
can drastically vary among viruses that infect the same host (25). For the first 60 or so years of 
virology, the nature of classifying viruses was hotly debated. Should it even be done, as viruses 
are intracellular obligate parasites, and are not in the traditional sense alive? However, as more 
viruses were discovered the need for a classification system become inherently relevant (25). 
In 1971 the seminal paper on the widely used classification system, for which he won the 
Nobel Prize in 1975, was published by David Baltimore (26). In the paper, he proposed a 
classification system based on the method of replication by viruses. Once viruses were classified 
by the method of replication, then further classification could take place based on the structure of 
the virion and host preferences. Baltimore first suggested 6 different families to classify viruses 
(Figure 1.1). This was later amended to include a 7th class as new data arrived, and a new 
family of viruses was needed (27, 28). Utilizing the genomic structure and method of viral 
replication was genius, given that DNA sequencing was very much still in its infancy and very 
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little was understood about viral life cycles at the time. Even more impressive, was that this 
classification system still holds true today, and has largely been able to characterize all the new 
viruses discovered. Remember, retroviruses like HIV would not be discovered for another 10 
years, but Baltimore was able to understand the literature so thoroughly and propose this class of 
viruses. 
The Baltimore classification system currently contains 7 groups of viruses all based on 
the genetic material and method used for viral replication. Each group can then be split and 
classified further based on the structural properties of the genome (i.e. linear, circular, or 
segmented genomes) and structural properties of the virion (1). Group I viruses (Figure 1.1), use 
a double stranded DNA genome to replicate and proceed to protein synthesis using an mRNA 
intermediate. Group I viruses have a varied genomic structure, containing linear, circular, 
segmented and circular, and segmented and linear genomes. This group contains a wide variety 
of pathogens, infect seemingly all types of living things (even some other viruses), and is 
classified based on morphology instead of sequence similarity. It currently contains 3 orders, 
which are further divided into 31 families of virus. Some clinically relevant viruses include the 
Herpesviridae and Poxviridae. The family of Herpesviridae is responsible for chicken pox, while 
the Poxviridae family hosts viruses like small pox, both of which have been nearly eradicated 
with vaccines (29-31). 
Group II viruses (Figure 1.1) contain a single positive stranded DNA genome. To make 
mRNA, the virus must first produce the template strand (- strand) and then can transcribe the 
mRNA for protein synthesis. This means that this virus goes through a double stranded DNA 
intermediate before proceeding to protein production. This group of viruses is most famous for 
bacteriophage Phi X174, which was discovered to have a single stranded DNA genome in 1962 
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(32). This genome was the first DNA genome to be completely sequenced by Fred Sanger in 
1977 (33). This group of viruses has proven hard to classify and is home to a diverse group of 
pathogens found throughout the environment. The morphological and genetic differences 
between the taxa of these viruses are often large, but efforts have been made to better classify 
these orders. The genomes of these viruses are notoriously small, and are mainly circular, with a 
few exceptions. One family of clinically relevant single stranded DNA viruses is Parvoviridae. 
Parvoviridae is home to the parvovirus, in which Parvovirus B19 was found to infect children 
causing a rash, while canine parvovirus can be highly lethal in unvaccinated dogs and is spread 
through feces (34, 35). 
Group III viruses (Figure 1.1) are double stranded RNA viruses which will transcribe 
RNA from the genome for both protein synthesis (mRNA) and viral replication. The genomic 
structure of this group of viruses is highly variable and can be either segmented or non-
segmented, with the segmented viruses containing up to 12 segments. Double stranded RNA 
viruses can infect a wide range of hosts including plants, animals, fungi, and bacteria. 
Furthermore, the variability of the structures of the virion in this class of viruses shows 
remarkable diversity. One clinically relevant pathogen belonging to this group of viruses is the 
rotaviruses belonging to the family Reoviridae. Rotaviruses are responsible for severe 
gastrointestinal distress and diarrhea in babies and young children and in 2013 was responsible 
for up to 215,000 deaths in the developing world (36, 37). 
Moving down the taxonomic groups, Group IV viruses (Figure 1.1) utilize a single (+) 
stranded RNA genome. Unlike many other viruses, this group can utilize the packaged (+) 
stranded RNA directly for protein synthesis. However, for replication to take place the negative 
strand needs to be synthesized, so more positive strands can be made for replication to be 
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complete. Largely classified based on the morphology of the RNA dependent RNA polymerase, 
the (+) stranded RNA viruses are home to the most RNA viruses, currently with 3 orders and 34 
different families being recognized. This group of viruses is perhaps most famous for the family 
Picornaviridae which is home to viruses like poliovirus, rhinovirus (the common cold), and 
Hepatitis A virus (38).  
Skipping over Group V viruses (Figure 1.1), as section 1.3 is entirely devoted to them, 
Group VI viruses also contain a single (+) stranded RNA genome. However, the mode of 
replication is very different from the Group IV viruses. Group VI viruses utilizes reverse 
transcription during its life cycle to mediate a DNA intermediate. This DNA intermediate is then 
utilized to create new (+) stranded RNA genomes. In the case of the widely known family of 
Retroviridae the DNA intermediate is incorporated into the host genome, known as a provirus, 
before replication takes place. The most famous virus in the group of viruses is HIV, which 
according to the Centers for Disease Control effected 36.7 million people and an estimated 1 
million people died from AIDS related illnesses in 2016 alone (39). While retroviruses have 
certainly caused much sorrow and death, the discovery and utilization of the reverse transcriptase 
enzyme has yielded many ground-breaking discoveries in biomedical research and is actively 
used throughout the research community today (40, 41). 
The last group of viruses, Group VII viruses (Figure 1.1), also utilize a reverse 
transcriptase and are another group of double stranded DNA viruses. However, unlike Group I 
viruses, these viruses also use a reverse transcriptase for replication. Group VII viruses will not 
only transcribe mRNA for protein synthesis, but also transcribe pre-genomic RNA. This pre-
genomic RNA, through reverse transcription, acts as a template and is transcribed back to DNA 
to replicate the genome. This is a relatively small group of viruses with two different families. 
11 
The most famous virus of this group is Hepatitis B virus, which is responsible for severe liver 
infections and can lead to hepatic cirrhosis and possibly hepatic cancers (42). While there is a 
vaccine available for Hepatitis B virus, if some individual contracts the virus there is no known 
cure. 
Viral classification is important to understand the different modes which viruses employ 
to replicate within a host. Virus taxonomy is still an ever changing topic and is continually 
monitored and changed by the International Committee on Taxonomy of Viruses (ICTV) (43). 
The ICTV has 4 main objectives as posted on their website: “to develop an internationally agreed 
taxonomy for viruses; to establish internationally agreed names of virus taxa; to communicate 
the decisions reached concerning the classification and nomenclature of viruses to virologists by 
holding meetings and publishing reports; to maintain an official index of agreed names of virus 
taxa” (44). As the ability for us to sequence genomes faster and cheaper continues to accelerate, 
the discovery of novel viruses will concomitantly quicken as well. Classification of viruses is 
becoming an important role, not only for monitoring viral evolution and infection, but also for 
adequately identifying and understanding novel viruses within the context of the known 
scientific literature. 
1.2.3 Antiviral Therapies 
The practice of understanding the structure-function relationships at the protein level has 
led to a giant leap in our basic understanding of the biological universe. This impact has not only 
been felt in the sciences but can also be directly correlated with the increase in life expectancy 
and increase in quality of life. From 2000 to 2015 the average world life expectancy has risen by 
5 years (Figure 1.2A)(The Global Health Observatory (GHO) data repository under World 
Health Organization (WHO)) (45). Furthermore, we have also seen an explosion in the number 
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of structures deposited in the Protein Data Bank (PDB) (Figure 1.2B) (46). When looking at the 
correlation between deposited protein structures and global life expectancy, one notices a 
significant positive correlation between the two (Figure 1.2C). While of course this is not a 
causative effect, but it is evidence that as our knowledge of protein structure has amassed the 
ability to apply this knowledge in a medically meaningful way has also gotten better. For 
example, the Federal Drug Association has approved a record number of new medications in 
2017 with 46 novel drugs approved (47). This implies that understanding the basic science 
behind these structure-function relationships is not only an intellectual curiosity, but it is of vital 
importance towards improving the over-all human condition. 
 While the understanding of structure-function relationships has continued to 
improve, there are certain areas where the basic science is lacking. One such area is in the 
development of antiviral drugs and antiviral treatments. With such pandemic outbreaks as the 
Ebola outbreak in 2014 (48) and the constant threat of the annual influenza outbreak, which costs 
U.S. workplaces approximately $7 billion annually (49), novel therapies are desperately needed. 
Luckily enough, in the cases outlined above, there has been a large push in recent years by the 
NIH to meet these needs (50). A success story in the application of structure-function 
relationships in drug discovery, was with the innovation of neuraminidase inhibitors (51-53). 
These inhibitors target neuraminidase activity in influenza, inhibiting the virus’ ability to 
reproduce by blocking the budding step (51). Two such drugs are now approved for use in the 
U.S. and Europe, oseltamivir and zanamivir, to treat both Influenza A and B. However, the 
efficacy of this class of drugs is widely debated and with treatment being most efficacious when 
the patient is treated early in the infection (54-57). Another class of drugs that has seen a recent 
success in antiviral therapies are polyamides. Polyamides have been long used to target the 
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minor groove of double stranded DNA in a sequence specific manner (58-60). Polyamides are a 
macromolecule with a repeating set of amide bonds. The interesting thing about these 
compounds is the chemical moieties can be changed to modulate specificity for a specific DNA 
sequence (60-62). Since these compounds can be designed for a specific DNA sequence, this 
leaves little room for off-target effects. Recently this class of drugs has been used to target the 
double stranded DNA virus, Human Papilloma virus (HPV), which is widely known to be 
implicated to cause cervical cancer (63-65). These compounds have been widely studied in in 
vitro and are hopefully going to make the move to being used in the clinic. For the context of this 
work, polyamides have been applied as a novel antiviral against a negative strand RNA virus, 
representing a new use for this highly versatile class compounds. 
 One cannot mention antiviral therapies without talking about vaccines. Vaccines 
are the most efficacious defense against viruses from all groups. Utilizing the power of our own 
immune system, vaccines have been extremely successful in preventing common diseases that 
were widespread for most of human history like smallpox, polio, whooping cough, measles, 
mumps, and rubella (66-69). Perhaps the biggest success story of vaccines is that of smallpox. 
Since 1980, the World Health Organization declared smallpox to be eradicated (69). This was a 
huge step for humankind as smallpox was the culprit of many pandemics throughout human 
history. While these vaccines have been very important towards bettering human health and 
longevity, further development is needed to combat other highly pathogenic viruses. One 
promising case, which arose from the Ebola epidemic from 2013-2016, which reportedly killed 
11,310 people with a mortality rate of 39.5%, is the invention of an Ebola vaccine (70, 71). In 
early vaccination trials, this vaccine is almost 100% effective at offering protection against Ebola 
infection (70, 71). These success stories around vaccines, are important to be shared with the 
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current combative climate surrounding vaccination. Since the anti-vaxxer movement has taken 
hold, diseases that have not been seen in decades, due to the success of vaccines, are once again 
on the rise (72, 73).  
While these results from antiviral and vaccines are certainly encouraging, for major 
advances to be made, and novel antiviral therapies to be produced, further understanding of the 
basic structure-function relationships of these viruses are vitally important to future generations. 
It is the hope of this work that through the study of the basic structure-function relationships, 
which guide viral replication, that guiding principles can be elucidated to better understand and 
design novel antiviral therapies. Utilizing both biochemical and biophysical techniques to 
unravel the structural complexity of these molecular machines can have a significant impact on 
human health, longevity, and well-being. 
1.3 Negative Strand RNA Viruses 
Negative strand RNA viruses (NSVs), or Group V viruses, are responsible for some of 
the most pandemic human pathogens known. This family of viruses is home to many of the well-
known and publicized hemorrhagic viruses such as Ebola, Marburg, and Lassa viruses, which 
can horrifyingly induce hemorrhaging from the gums, eyes, nose, and other orifices (Figure 
1.3B). They are also famously involved in thousands of deaths (i.e. the Ebola outbreak in 2013-
16) (74, 75). Another pathogen which is a part of this family is the seasonal flu (Influenza A and 
B), which the Centers for Disease Control (CDC) estimates is responsible for anywhere between 
12,000 and 56,000 deaths in the U.S. every year (76). Furthermore, this family also includes 
diseases which are deemed largely under control due to the development of vaccines (i.e. 
Measles, Mumps, Rubella, Rabies), but are now making a return with the “antivaxxer” 
movement and rapidly developing resistance (73). Also, Human Respiratory Syncytial Virus 
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(RSV) is an NSV which is the leading cause of lower respiratory tract infections during infancy 
and early childhood. It will usually infect almost all children by the time they reach 2-3 years of 
age and is one of the top reasons for childhood hospitalization (77). As one notices, NSVs are 
responsible for a wide range of human illnesses, hospitalizations, and death. It is fascinating that 
this group causes such a wide range of symptomatic phenomena and is also extremely 
promiscuous in its choice of hosts: infecting vertebrates, arthropods, and even plants. 
Despite being so promiscuous, this group of viruses share several common traits. As 
mentioned in the chapter on virus classification, viruses can be classified by their mode of 
replication. NSVs utilize a negative sense genome as its genetic material. Unlike positive strand 
RNA viruses, which can directly utilize their RNA for translation of viral proteins, NSVs must 
go through a transcription step in order to create the necessary mRNA for protein translation 
(Figure 1.3A) (78, 79). In doing so, instead of relying on the host’s polymerase machinery, this 
group has evolved to bring along their own, called the viral RNA dependent RNA polymerase 
(vRdRp) (80-82). Additionally, for this group of viruses to replicate, it must first transcribe a 
sufficient amount of viral proteins, and then initiate replication by creating a complete 
complementary genome (cRNA) (Figure 1.3A). Then the polymerase complex must re-copy the 
cRNA back to the normal negative stranded genome (vRNA). This mode of replication is unique 
to Group V viruses, and they have come up with interesting ways to achieve this goal.  
Another commonality of this group of viruses is that the genome during entry, assembly, 
transcription, and replication, must be encapsidated by a capsid protein (83-88). This means that 
at every point of the life-cycle, the viral genome is protected by a capsid protein. Moreover, for 
the polymerase to partake in transcription/replication it must bind to the capsid protein and 
access the encapsidated RNA. This makes accessing the genome an imperative step for 
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transcription and replication to occur. This is unique for this group of viruses: the vRdRp can 
only recognize the protein RNA template for transcription and will not transcribe the naked 
genomic RNA. This adds an extra layer of regulation in the production of RNA and protein 
levels in this group of viruses. 
This family of viruses can also be split into two distinct groups based on the structure of 
the genome: segmented and non-segmented. Segmented NSVs, as the name implies, have a 
segmented genome, with each segment encoding for a specific protein or proteins. While non-
segmented NSVs have a continuous linear genome with each gene being separated by intergenic 
regions controlling transcription. For segmented NSVs, each segment is individually 
encapsidated and then packaged separately into the virion, and often exhibit a circular helical 
structure (87). This means that each ribonuclear protein (RNP) in segmented NSVs acts as a 
functionally independent moiety during transcription and replication. Whereas non-segmented 
NSVs contain a continuous linear genome which is usually packaged into a tight helical structure 
(85, 89, 90). Since all of the genes are part of a continuous RNA strand, this means that each 
gene is sequentially transcribed allowing for a protein gradient to form (91). While this 
represents two different modes of transcriptional control, it is interesting that for segmented 
NSVs, this allows for substantial levels of recombination to occur during a superinfection. This 
possibly leads to the generation of species hopping strains, which often observed during 
influenza infections (92, 93). Whereas in non-segmented NSVs this phenomenon does not occur. 
1.3.1 Evolutionary Control of Genetic Drift 
One interesting phenomena, actively discussed and explored in this dissertation, is how 
NSVs controls their genetic drift. Due to the nature of RNA transcription, NSVs often have 
surprisingly high mutation rates. This has been traditionally explained by the fact these viruses 
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bring along their own transcriptional machinery. Having a high mutation rate can serve as an 
evolutionary advantage due to the presence of quasi-species and possible beneficial mutations 
(94, 95). It has been noted that Paramyxoviridae exhibits a high enough mutation rate to 
completely randomize the entire genome up to 6 times per year (96). However, the observed 
mutational rate is only around 6 nucleotides per year (96). This creates a dichotomy, and begs the 
question: how can the genomic sequence of these viruses be so stable, in the presence of such a 
high mutation rate? 
One way that these viruses could adequately control this phenomenon, is through the 
optimization of their Codon Usage Bias (CUB) and Codon Pair Bias (CPB). For efficient 
translation by the host, the virus must match the host’s CUB. CUB can be defined as the 
percentage of a codon used for a selected amino acid during translation. This bias has been found 
to differ across species and throughout phyla. This is usually attributed to the abundance of 
tRNAs that are available for the host to use. CPB is related to how often codons are 
synonymously paired with each other throughout a sequence, which can be a direct consequence 
of CUB. It has been widely shown that positive strand RNA viruses match their CUB/CPB with 
that of the host organism’s (97). Furthermore, it has also been shown that one can create a live 
attenuated virus, just by changing the CUB/CPB of Poliovirus (a positive stranded virus), and not 
the encoded proteins (97, 98). This technique has been used for the past decade, and is currently 
under intense investigation (99). However, while this works for positive stranded RNA viruses, 
this does not mean it will be the same for NSVs. Not only will the host’s translational machinery 
play a role in regulating genomic processivity, but also NSVs bring along their own 
transcriptional machinery for mRNA synthesis. This makes it another checkpoint for 
transcriptional/replication control. Furthermore, the CUB/CPB in NSVs, for some reason do not 
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actually match with their host’s (Table 4.4 in Chapter 4). Leading to another level of mystery as 
to how they regulate their genomic drift.  
Another level of evolutionary constraint against NSV genomes, is the suppression of 
CpG. It has been widely noted, especially in DNA viruses, that CpG is widely avoided in viral 
and pathogenic infections. This is usually due to two different factors: avoiding genomic 
methylation and evasion of the innate immune response. In DNA CpG is often avoided due to 
the methylation of C to a T, circumventing a level of epigenetic control and or mutational 
hotspots. Also, CpG is avoided to help the parasite evade the innate immune response through 
interaction with TLR9 (100-103). While NSVs have been shown to avoid CpGs, this correlation 
has been shown to be not as strong—as in a positive strand RNA virus like polio (104, 105). 
However, while it is widely understood in the context of DNA, there is contradictory evidence in 
the literature as to whether this actually applies to RNA viruses (106). Some evidence points 
towards CpGs directly interacting with toll like receptors (TLRs) 3, 7, and 8 and inducing an 
immune response, however at the cellular level this CpG activation has yet to be observed (107, 
108). While it is interesting that CpGs are largely avoided throughout all RNA viruses, and most 
likely plays a role in avoiding the immune system, it would not be a large enough factor to 
control the transcriptional machinery and stabilization of the genome.  
Finally, the last level of constraint on NSV genomes is the structural properties of the 
transcribed mRNAs. For optimal translation to occur, the secondary structure of the mRNAs has 
a direct effect on not only the speed of translation, but also in the resulting protein structure (109, 
110). One example occurs in HIV. It has been shown that the secondary structure of mRNA in 
the gag polyprotein and envelope protein of HIV slows down translation and allows for proper 
protein folding (111). While this could play a significant role in controlling the translation of 
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proteins, and influence protein folding, it may also be a level of constraint on the genomic 
sequence. However, this may be especially important when it comes to the translation of the 
mRNAs available in positive strand RNA viruses. In NSVs, while this is certainly an 
evolutionary constraint, we have hypothesized another level of genomic control, all based on the 
transcription by the vRdRp. 
Later in this work, we have put forward a model that considers the interactions between 
the genomic viral RNA and the nucleoprotein. We postulate that the interactions between the 
genomic RNA and the nucleoprotein have a direct effect on the processivity of the vRdRp. Since 
the polymerase must open the nucleocapsid to access the sequestered RNA, there must be some 
genomic sequences which will have more interactions between the nucleoprotein and the RNA. 
This would make certain sections of the nucleocapsid harder to access, while making other 
sections easier. Altering the accessibility of the RNA in certain spots, would influence the overall 
processivity of the vRdRp. In the work presented in Chapter 4, it was found that just by changing 
the nucleotide content of the genomic sequence, and not the encoded protein sequence, the 
activity of the vRdRp drastically decreased. Furthermore, the model is corroborated with a 
sequential analysis of the genomic content and in vitro melting experiments of the nucleocapsid-
like particles (NLPs). These experiments point toward genomic base stacking as being the main 
driving force behind modulating the accessibility of the vRdRp. This paradigm shifting model, 
represents a completely novel way of thinking about how NSVs modulate their 
transcriptional/replicational machinery.    
1.3.2 Vesicular Stomatitis Virus 
In this dissertation, Vesicular stomatitis virus has been chosen as the model pathogen for 
all the presented investigations. Vesicular stomatitis virus (VSV) has traditionally been used as a 
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model pathogen for investigating the basic science behind the guiding principles of non-
segmented NSVs (112). It is the ideal model system due to its simplicity and transferability when 
investigating the NSV family. It has a similar architecture to other more pathogenic viruses like 
Ebola, Marburg, Rabies, and RSV, but is relatively non-pathogenic in humans (112, 113). It’s 
native host is cattle and carrier is the sand-fly, however, it can still infect humans causing mild 
flu-like symptoms (114). Also, VSV has been shown to be adaptable, being able to tolerate the 
addition of many different proteins to its genome—making it an excellent candidate for cellular 
level studies (115, 116). It is for this reason that VSV is chosen for all the studies presented in 
this work. 
Belonging to the family Rhabdoviridae, and closely related to the Rabies virus, VSV is a 
simple NSV having a genome that is only 11.2 kb encoding for 5 different genes (1). It is a non-
segmented NSV and the 5 genes get transcribed sequentially to produce a protein gradient with 
the first gene being most abundant, and the last gene being least abundant. The first gene encodes 
for the nucleoprotein (N). The nucleoprotein is responsible for sequestering the genome, serving 
as the template for transcription and replication all the while sequestering and protecting the 
RNA. The second protein, known as the phosphoprotein (P), acts as a chaperone protein to bring 
the polymerase to the nucleocapsid and assists in the formation of the vRdRp. The matrix protein 
(M) primarily assists in the assembly of the virion, aiding in packaging of the viral proteins to 
form the classical bullet shape of VSV. The glycoprotein (G) is purely responsible for mediating 
cell entry through clathrin-mediated endocytosis. Finally, the large protein (L) is the polymerase 
protein, which is made up of 5 different domains, containing a typical RNA-dependent RNA 
polymerase (RdRp) domain, a capping domain (to synthesize the 5’ caps on mRNA), and also a 
methyltransferase domain (117). Combined with the N and P-proteins, they form the entire 
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vRdRp complex (118). Something which is very interesting to note, is that the polymerase 
protein will not recognize the nascent RNA molecules and be able to carry out its chemistry. It 
must recognize the nucleocapsid template, chaperoned by the P-protein, in order for transcription 
to take place (119).  
While it is important to have an overview of the function of each protein in VSV, it also 
important to know the overall structure of the virus (Figure 1.3C). It is within these structural 
properties, from which the functions begin to arise. Starting from the outer layer-working in, 
VSV is a bullet shaped, enveloped virus. This envelope is made up of a phospholipid bilayer 
gained while budding off during replication (120). Embedded in this envelope is the 
glycoprotein.  The glycoprotein completely encompasses the outside of the virus and can assume 
three different conformational states: a native state which is abundant on the outside of the virus 
at pH 7; an activated hydrophobic state to target the membrane bound receptor (prefusion); and 
the post-fusion state taking place at low pH after viral entry (121-125). The prefusion structure, 
allows the VSV glycoprotein to bind to the surface cellular receptor. However, once the virus 
enters the cells via endocytosis the pH drops to 4. This change in pH mediates a structural 
rearrangement of the glycoprotein. The prefusion glycoprotein is dimeric, while the low pH post-
fusion glycoprotein structurally rearranges to a trimer. The G-protein of VSV is quite unique in 
that it does not act like a traditional class I or II viral fusion protein—it has properties that mimic 
both. This has lead researchers to speculate that it could belong to a new category of fusogenic 
glycoproteins. Recently, it was found that the putative receptor target for the VSV G-protein is 
the LDL-receptor family. Structural evidence points towards the G-protein targeting two cysteine 
rich domains, called CR2 and CR3, with identical binding motifs to the different regions (126).  
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Working our way inward (Figure 1.3C), the matrix protein (M) is dispersed around the 
outer layer of the virion (90). The M-protein is promiscuous in its functions throughout the VSV 
life cycle. One role is to serve as a structural protein to initiate packaging and budding of the 
virion. It binds the nucleocapsid protein to initiate the helical packaging of the capsid, while 
simultaneously stopping viral transcription and replication (127-129). Also, it binds very tightly 
to the cell membrane and in vivo experiments have shown that even 2M KCl or a pH of 11 
cannot disrupt these interactions. This is indicative of its role in the viral life cycle, packaging the 
contents of the virion into a cell membrane bound vesicle to eventually bud off. This role, in 
mediating viral packaging and budding has been thought to be facilitated through the M-proteins 
interactions with Dynamin (130). Dynamin is a GTPase which is responsible for the formation of 
vesicles for clathrin-mediated endocytosis (131). This would provide the driving force for virion 
budding, to form a new vesicle. The second role which the M-protein plays during the viral life 
cycle has to do with the inhibition of various host proteins. It is able to block the host’s ability to 
do translation and transcription (132, 133)  and mediates viral evasion of the immune system 
(127). It has been postulated that the M-protein may suppress the immune system through 
multiple different modes. One way that the M-protein achieves immune suppression is through 
inhibition of the Beta Interferon gene (127). The M-protein has been found to be directly 
correlated with the suppression of Beta Interferon. Suppression of Beta Interferon, would 
dampen the immune response to VSV infection and allow it to proliferate to nearby cells (134). 
The M-protein also blocks the host’s ability to do transcription and translation. While the 
methods to which the M-protein achieves this are still highly debated, one way might be through 
binding to a complex of Rae1 and Nup98 (132). Rae1 is a protein with an uncertain function, but 
is known to be localized in the cytoplasm, nucleoplasm, and the nuclear rim (135). It can form 
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many different oligomers and has been found interact with Nup98 (136). Nup98 is a nucleoporin 
protein responsible for creating a pore for mRNA to be transported outside of the nucleus (137). 
It was found that the matrix protein readily interacts with the Rae1-Nup98 complex (132). 
Furthermore, if Rae1 is silenced, host gene expression was not affected, and it increased the 
cell’s ability to resist M-protein induced transcriptional silencing. This indicates that 
transcriptional silencing is not mediated through the formation of an M, Rae1, Nup98 complex, 
but through the interaction of the tripartite complex with some unknown moiety. This unknown 
complex is hypothesized to inhibit host transcription and replication.  
When it comes to VSV replication, the M-protein displays a surprisingly diverse range of 
functionalities. Not only is it involved in the process of viral assembly and eventual budding but 
is also directly implicated in the virus’ ability to evade the immune system. However, perhaps 
the most interesting and under explored area of research is how the M-protein inhibits the host’s 
transcriptional and translational machinery. Without a thorough understanding of this role, it is 
almost certain that VSV would not be able to efficiently replicate. This small protein displaying 
such a wide array of functions is the epitome of viral proteins. Having this wide array of 
functions, especially for a small virus like VSV, is one of the very important mysteries that must 
be untangled to fully understand VSV infection. 
As we continue to work our way into the virus, the proteins that make up the vRdRp are 
left. Inside the layer of the matrix protein, is the nucleocapsid protein (N)—this protein will be 
discussed at length later in this chapter. Seemingly randomly dispersed throughout the bullet and 
attached to the nucleocapsid are the Phosphoprotein (P) and the polymerase (L) (Figure 1.3C). 
Along with the N-protein, these three proteins form a complex to create the active vRdRp. It is 
important to note that the vRdRp needs all three proteins to carry out transcriptional chemistry. 
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The polymerase cannot transcribe the RNA if it is not encapsidated by the N-protein. The overall 
structure of the vRdRp has yet to be solved, but many functional studies have been done 
regarding the interactions that dictate this complex (138-143). However, it is without reservation 
that until the structure of the entire vRdRp can be solved, the basic science behind this important 
complex will be hard to unravel. Once this structure has been solved, the parameters that regulate 
this complex will then be able to be actively studied and applied to other pathogenic viruses. 
However, a lot of information can be gleaned by studying each protein independently.  
The P-protein, plays an interesting role in the formation of the vRdRp. It acts as a 
chaperone for the L-protein to bind the nucleocapsid (144). Sections of the P-protein’s structures 
have been solved both alone and in complex with the N-protein—it is also present in the L-
protein structure, but the density is not clear. The P-protein can be thought of having 3 different 
domains: the N-terminal domain, the Oligomerization domain, and the C-terminal domain (145, 
146). Each domain has been structurally characterized separately. Both the N-terminal domain 
and the C-terminal domain have been solved in complex with the N-protein, while the 
Oligomerization domain has been solved by itself (141, 145, 147). According to the structural 
evidence, the N-terminal domain is important for binding what has been called the N0 complex 
of the nucleocapsid. This complex is the first complex formed before any RNA has been 
transcribed by the vRdRp (148, 149). This is an important step which occurs only during 
replication and would represent the first step of replication. The C-terminal domain of P binds 
the flexible C-terminal loop of the N-protein—far from the encapsidated RNA (141). Upon the 
C-terminal domain binding, the flexible loop on the N-protein becomes stabilized. Based on the 
structural evidence, this is believed to be an area where the P-protein is attached to the 
nucleocapsid. This is important for the formation of the vRdRp. Finally, the Oligomerization 
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domain is purely responsible for dimerization of the P-protein. Dimerization of the P-protein 
through the oligomerization domains is important for the processive interactions between the N 
and L-proteins (145). It is believed that oligomerization of the P-protein potentiates its chaperone 
activity. Through dimerization, one monomer could interact with the nucleocapsid, while the 
other interacts with the L-protein.  
While P is an important factor in the formation of the vRdRp, it potentially has some 
control over viral RNA synthesis (150, 151). The P-protein, aptly named, can be phosphorylated 
in many different positions (152-156). There have been many studies which link phosphorylation 
of certain regions on the P-protein to viral RNA synthesis (157, 158). One particular study, 
utilizing mass-spectrometry on the authentic virus, identified Tyr 14 on the N-terminal domain of 
P to be of vital importance in facilitating viral RNA synthesis only during replication (159). 
Furthermore, in the same study the authors noted other phosphorylation sites only play a role 
during transcription. This leads to interesting suggestions of how different phosphorylation 
patterns within P could impact viral transcription/replication. This would be plausible, as the 
virus needs various ways to control its viral transcriptional machinery. 
The L-protein, carries out all the polymerase activity for VSV. The L-protein is the 
largest protein in the genome, far surpassing the other proteins in size. For this reason, it also is 
the protein that has been the hardest to characterize. It wasn’t until a couple of years ago (2015) 
when a Cryo-EM structure was finally solved for the L-protein (117). It was the first full-length 
polymerase structure to be solved in this family of viruses. The L-protein is versatile and can 
carry out all the associated polymerase activities, including capping, methylation, and 
polyadenylation (160-163). The L-protein contains 5 different domains with different functions. 
It contains the canonical right handed “finger-palm-thumb” structural motif which can be found 
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in many polymerase complexes (164). This has been called the RdRp domain and is where the 
transcriptional chemistry occurs. This “finger-palm-thumb” structural motif is surprisingly 
conserved, even in the heterotrimeric influenza virus polymerase complex. This structural 
conservation extends from about residue 107-866 (the end of the RdRp domain) in VSV-L and 
from 415-714 of the PA subunit/8-586 of the PB1 subunit in human influenza B virus (117, 165, 
166). This shows that similar mechanisms garner the control of transcription in many of these 
viruses. 
The Capping Domain (A.A. 866-1334) is responsible for capping the 5’ end of the viral 
RNA. As of now, this domain has no structural homologues and synthesizes the 5’ cap in an 
unusual way. The host capping mechanism relies mainly on a guanylyl transferase, whereas the 
chemistry in the capping domain is different. In short, the 5’ end of the RNA is covalently linked 
to a histidine residue (H1227). This linkage is then attacked by a guanosine nucleotide, capping 
the RNA and releasing the covalent linkage. This classifies the capping mechanism as a 
polyribonucleotidyl transferase (PRNTase) (117). Furthermore, there are two different postulated 
metal binding sites in this domain. Being far away from the active site, they are postulated to 
bind Zn and are believed to only play a structural role in the protein. Also, this domain is the 
home to a priming loop. While it is known that VSV L does not need a primer to initiate 
transcription, it has been postulated that the priming loop could either be used to enhance the 
fidelity of the polymerase, by sterically slowing it down, and/or by coupling capping to initiation 
of transcription polymerization. 
Moving to the next domain, the Connector Domain (A.A. 1358-1557) appears to be a 
strictly structural domain. It places the catalytic subunits in the correct position for efficient 
catalysis (117). Bordered by two different disordered linkers on the N-terminal and C-terminal 
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sides, this domain is made up of a bundle of eight helices. The Connector Domain, is also 
postulated to be the place where P may interact with L. To solve the cryo-EM structure of the L-
protein, the authors incorporated the N-terminal domain of P during protein purification. 
However, the authors were not confident of the placement of the fragment in this region but 
noticed some extra undefined density (117). The authors postulated that this portion of P is 
responsible for binding to the Connector Domain and stabilizes the L-protein in this structural 
conformation. This would allow the L-protein to assume a stable structure for the correct 
placement of the catalytic domains during viral transcription. 
The Methyltransferase Domain (A.A. 1598-1892) is able to methylate both the N7 on 
guanosine and O2’ on the conjugate ribose. It does so by transferring this methyl group from the 
canonical S-adenosyl methionine, the ubiquitous methylation substrate utilized by many different 
enzymes (167). It has a similar structural configuration with other flavivirus methyltransferases 
as well as some other methyltransferase enzymes (168-170). Interestingly, the authors stated that 
there is no tunnel through the protein that connects the methyltransferase domain with the RdRp 
domain in this conformation (117). However, this would make sense as the structure of the L-
protein is not bound to the nucleocapsid. It would be pertinent to predict that upon binding the 
nucleocapsid, a significant structural rearrangement would occur and cause these domains to 
come in closer contact. A direct path from the methyltransferase domain to the RdRp domain is 
needed to produce a viable 5’ cap for the mRNA transcripts. However, this tunnel would be 
useless during replication. This would indicate that there are multiple structural conformations 
which the L-protein could assume during viral RNA synthesis.  
Finally, the last domain of the L-protein is the C-terminal domain. Like the Connector 
domain, the C-terminal domain likely plays a purely structural role (117). It consists of a bundle 
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of alpha helices and a 25 residue C-terminal arm. This arm protrudes from the C-terminal 
domain and loops back towards the RdRp domain and interacts with the previous capping, 
connector, and methyltransferase domains. This structural feature seems to be conserved among 
negative stranded RNA polymerases, but the current function is currently unknown (117). 
Overall, the L-protein exhibits an incredible array of functions. Much is left to be 
discovered concerning both the structure and the mechanism of this protein. Moreover, the 
elucidation of the entire vRdRp complex, would be a break through discovery for understanding 
how viral RNA synthesis of VSV occurs. Currently it is postulated that the L-protein binds the 
nucleocapsid and opens three subunits at once, revealing the sequestered RNA (141). During 
replication, as the RNA is being transcribed it will immediately be encapsidated by an empty 
nucleoprotein. The polymerase will then open the subsequent subunit while closing the previous 
one. Obviously, this would mean that there are multiple catalytic structures/rearrangements that 
must occur for this chemistry to work. This fascinating system is similar to other non-segmented 
RNA viruses. As evidence, both the nucleocapsid and L-proteins show high sequence identity 
and similar domain organizations as Rabies, Ebola, Measles, and RSV (117). This would 
indicate that understanding the basic science behind VSV and its viral RNA synthesis, can be 
applied to many other important pathogens. 
As a model system, VSV helps clarify the guiding principles behind many viral 
mechanisms. The study of VSV has also led to many potentially breakthrough treatments (171, 
172). It is used as the main vector in the highly publicized Ebola vaccine (70), which some 
vaccination studies have found it to be 100% efficacious. This vaccine is created by adding the 
glycoprotein of Ebola to VSV, which substantiates a robust immune response in humans. This 
shows that studying VSV does not only allow one to discover the underlying basic science 
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behind more pathogenic viruses but can also be adapted towards the development of vaccines. 
The ability of VSV to be such a highly translatable tool is the reason it is used as the model 
system throughout this work. 
1.4 Literature Review of the Nucleocapsid in Vesicular Stomatitis Virus 
As outlined in the previous section, the nucleocapsid is responsible for sequestering the 
genomic material of the virus (89). Being part of the vRdRp complex, it plays a vital role in viral 
transcription and replication (118, 141, 160). Since the RNA is sequestered in the nucleocapsid, 
the L-protein must open the nucleocapsid and abstract the RNA for transcription/replication to 
occur. In this case, the L-protein cannot carry out its polymerization chemistry on naked RNA 
alone, it must utilize the protein-RNA template for transcription to occur. Biochemically, this 
unique system represents an exceptional chance to study the latent interactions that can occur 
when dealing with transcription from a protein-RNA complex. Unraveling these interactions 
reveals how nature can apply ubiquitous chemistries in unorthodox ways. Biologically this 
system yields the opportunity to examine more clinically relevant questions like: Can the 
nucleocapsid be a good target for a novel, transferrable antiviral? And what are the constraints 
placed on NSV viral RNA synthesis? When coupled with a multi-faceted understanding of 
biochemistry, answering these questions can lead to some important answers. As the 
nucleocapsid of VSV is focus of this work, it is important to understand what is already 
understood in the literature.   
The structure of the nucleoprotein (N) of VSV in complex with RNA was solved by our 
lab back in 2006 (89). This was the first structure of its kind to be solved and was published 
simultaneously along with the nucleocapsid protein structure from Rabies (85). It was in these 
two seminal papers that revealed the intricate intermolecular interactions which guide the 
30 
assembly and encapsidation of the viral RNA. The N-protein is made up of two distinct lobes: 
the N-terminal lobe and the C-terminal lobe (Figure 2.1 in Chapter 2). Sandwiched between 
these lobes is a pocket where the RNA is sequestered. Each monomer of the N-protein interacts 
with 3 other monomers of the nucleocapsid protein (89). It does this using a protruding N-
terminal arm and flexible C-terminal loop, both of which are important for both assembly and 
RNA encapsidation. On the N-terminal lobe is the N-terminal arm. This N-terminal arm is 
anchored into an adjacent C-terminal lobe through multiple interactions. Furthermore, to further 
enhance these interactions, the C-terminal loop interacts with a previous C-terminal lobe and an 
N-terminal arm. This creates a tightly interweaved intermolecular assembly between the 
nucleocapsid proteins. 
Located between the N-terminal lobe and C-terminal lobe, the genomic RNA sits in a C-
shaped binding pocket. The RNA encapsidated by the N-protein is highly structured. Each 
subunit encapsidates 9 nucleotides. With a slight helical structure, the encapsidated RNA closely 
resembles a single stranded B-form RNA. Furthermore, it has a unique base stacking pattern 
which is repeated throughout each subunit (89). Nucleotides 1-4 base stack with each other, 
while nucleotide 5 base stacks with 7 and 8. Nucleotide 6 is flipped in the opposite direction and 
does not base stack with any other nucleotides, while nucleotide 9 is labile and is able to base 
stack first nucleotide in the adjacent subunit. This base stacking pattern is sequence independent. 
The structures of the nucleocapsid were solved with all of the of polynucleotides available: 
poly(rA), poly(rG), poly(rC), and poly(rU) (173). Comparing these structures to the randomly 
encapsidated RNA from the recombinantly expressed protein showed that the global structure of 
both the RNA and protein do not change with sequence (173). While the structural properties of 
both the RNA and protein do not change, it was noticed that the occupancy of the RNA changed 
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slightly with differing nucleotides. This would suggest that the nucleocapsid modulates 
nucleotide binding in some unforeseen way. Additionally, a mutational study of the amino acids 
present within the RNA binding pocket revealed complete abolishment of RNA binding. Both 
biochemical and crystallographic evidence show that the mutant S290W cannot encapsidate 
RNA (174). The bulky W side chain encompasses the pocket and blocks RNA from being 
encapsidated while preserving the intricate intermolecular interactions relevant to assembly. This 
structure indicates, and another structure which was solved without RNA (173), that the 
nucleocapsid assembly is independent of RNA binding. This means that assembly of the 
nucleocapsid occurs with or without RNA present. Also, once the nucleocapsid is assembled it 
retains the ability to encapsidate RNA. 
   There are two structures that have been solved of the nucleocapsid protein in complex 
with a fragment of the P-protein: the C-terminal domain of P and the N-terminus of P (141, 147). 
Both complexes are unique and presumably represent different stages of transcription and 
replication. The structure of the C-terminal domain of P (PCTD) and the N-protein (N/PCTD) 
can only occur when the N-protein is fully assembled. The PCTD binds at a site formed between 
two different subunits on the top of the C-lobe (141). It binds a part of the C-terminal loop and α-
helix 13 on the N-protein. PCTD is comprised of 5 α-helices and an antiparallel β-turn. 
Interestingly, the overall structure of both the PCTD and N-protein do not change after forming 
the complex. Overall, 24 hydrogen bonding interactions aid in forming the complex with 19% of 
the total surface area of PCTD contributing to the creation of the N/ PCTD complex. This 
structure represents a significant step in understanding the pertinent interactions associated with 
the formation of the vRdRp. Since P acts as a chaperone to bring the L-protein to the 
nucleocapsid, understanding these interactions through a direct method allows for the design of a 
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model of replication. Using this structure, one can predict that the PCTD could be largely 
responsible for transiently anchoring the L-protein in an optimal position for access to the 
sequestered RNA in the nucleocapsid. In doing so, the PCTD needs to be able to simultaneously  
both bind and release the nucleocapsid as the polymerase moves down the genome (141). While 
this structure may not necessarily be relevant to both transcription and replication, it is unknown 
as to which part of the replication cycle this structure represents. However, it provides an 
important molecular snapshot of the viral life-cycle and yield important information about the 
formation of the vRdRp. 
Another sought after structure is the N0 structure. To be best defined, the N0 structure is 
an empty N/P complex formed during the initial step of replication. This structure has been 
proposed to act as a switch, triggering the vRdRp to change from transcription to replication. The 
hypothesis is that after a significant protein build up, the N0 complex forms and binds to the 
vRdRp (148, 149, 175). The act of binding initiates a change from transcribing protein, to 
replicating the entire genome. It would first form +cRNA and then -vRNA. During transcription, 
the product of the vRdRp is mRNA, which is then translated and packaged into proteins. 
However, during replication the nascent RNA needs to be immediately encapsidated. This is 
because the polymerase complex must then re-copy the entire genome to complete viral 
replication—the RNA produced cannot go on to produce protein. Thus, the formation of the N0 
complex a critical step in the viral life cycle. In the literature, there is a proposed N0 structure 
(147). Multiple studies have confirmed that a truncated N-terminal arm, when co-expressed with 
full-length P will yield an interesting RNA free 2P-N complex, but this has yet to be fully 
structurally characterized (112, 147). In the putative N0 structure the truncated N-protein is in 
complex with a portion of the N-terminus of the P-protein (P60). Like the previous data this N0 
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structure is also RNA free. In solution, this complex forms monomeric heterodimers (1:1 P:N), 
while in crystallo it forms the traditional decameric complex. The binding mode of P60 sits 
between the N-subunits and blocks a part of the RNA cavity. This fragment also occupies the 
same space as the N-terminal arm. Using Small Angle X-ray scattering and Size Exclusion 
Multi-Angle Light Scattering to compare the crystal structure to the structure in solution, the 
authors found that these complexes are structurally similar. Furthermore, NMR data confirms the 
crystal structure configuration but suggests that there is a high degree of solvent exchange on the 
first 17 residues of P60. This indicates that N-terminal portion is conformationally flexible but 
prefers the more stable in crystallo orientation (147, 176). This structure shows that P does not 
only chaperone L to the nucleocapsid for transcription to take place, but also brings the 
monomeric nucleoprotein to the nascent RNA being produced by the vRdRp. While this 
structure certainly reveals a molecular snapshot of a possible N0 complex, more work throughout 
the field needs to be done to further investigate its role. 
While the complexes of the N and P-proteins have revealed a lot about the molecular 
underpinnings which control RNA encapsidation, very little is known about the molecular 
architecture of the tripartite complex that forms the vRdRp. Functional mutational studies have 
attempted to clarify this (177), and are certainly worth exploring, but the actual contacts cannot 
be mapped until the structure is solved. Utilizing the knowledge gained through the elucidation 
of the nucleocapsid structure, an aim of this work is to functionally characterize a selected region 
which was hypothesized to be critical for the formation of the vRdRp. Mutational studies when 
guided by structure, can be a great guide to reveal mechanism and architecture in the context of a 
viral infection. Unfortunately, without a complete structure of the vRdRp conclusions drawn 
from these types studies must be validated using other biochemical methods. However, once the 
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structure of the vRdRp is solved, the functional information present in the literature becomes the 
foundation for determining mechanism. 
In this family of viruses, the nucleocapsid protein is paramount to the viral life cycle. 
Playing the crucial role as the gatekeeper to the genome, means that it has many functions. 
Throughout this work many differing aspects of this protein are thoroughly examined and a 
background of the existing literature is actively needed. As it comes to the structure-function 
relationships of this protein there are still many mysteries yet to be resolved by the literature. 
This work is meant to take a step in the direction of further clarifying the basic mechanisms 
which guide NSV replication.   
1.5 Research Objectives and Synopsis 
This dissertation aims to investigate the basic chemical properties controlling the 
biological processes surrounding the nucleocapsid protein of vesicular stomatitis virus and how 
these processes regulate the activity of the vRdRp. Furthermore, across all NSVs, the 
nucleocapsid exhibits stunningly high levels of structural conservation. In this light, all the 
presented studies have been designed to be applicable in the context of the wider family of 
NSVs. Utilizing a highly interdisciplinary approach, with techniques taken from Biochemistry, 
Molecular Biology, Biophysical Chemistry, Bioinformatics, and Virology, this dissertation can 
be viewed through a three-tiered lens: 
1. Development of Novel Antiviral Therapies 
2. Further the understanding of the architecture of the viral RNA dependent RNA 
polymerase through mutational studies 
3. Elucidate the genetic constraints on the RNA Polymerase which control viral 
RNA synthesis 
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Examining the first lens, the development of antiviral therapies is not only good for 
eradicating diseases but also can be useful to aid in the understanding of basic biological 
functions. Furthermore, using rational drug design and preexisting classes of compounds, 
specific antivirals can sometimes be found with little off target effects and toxicities. In the case 
of this study, a polyamide was adapted to target the encapsidated RNA in VSV. Polyamides are 
well-known class of compounds that can specifically target the minor groove of DNA. They are 
well studied with relatively low toxicities and can be targeted to specific sequences of DNA (61, 
62). Also, they have been found to be an effective antiviral agent against HPV and are currently 
under further development (63, 65). In this study a polyamide was found that can target the RNA 
in the nucleocapsid of VSV and inhibit viral RNA transcription. While this compound is specific 
for VSV, this is the first known case in the scientific literature of a polyamide targeting viral 
RNA. Also, the knowledge gained in our approach can be used to develop other polyamides 
against a multitude of NSV infections. 
Exploring the second lens, understanding the interactions that drive the assembly of the 
vRdRp in VSV is still an ongoing research topic. While every protein in VSV has either had the 
entire or a portion of the structure solved by Cryo-EM or X-ray Crystallography, the architecture 
of the vRdRp and how the proteins interact with each other remains elusive. To obtain an active 
vRdRp, three proteins need to be present: the Nucleocapsid, the Phosphoprotein, and the 
Polymerase (or L-protein). To fully understand the transcription and replication processes, the 
interactions guiding both the assembly and function of the vRdRp need to be fully elucidated. 
Without a crystal/Cryo-EM structure, alanine scanning mutation studies represent a viable 
biochemical method to tease out intricate interactions between the proteins. In this study, 
utilizing previous structural information, mutations around a proposed RNA “access gate” 
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proved to abolish almost all vRdRp activity. These mutations did so without interrupting the 
global structure of the nucleocapsid, indicating direct interaction by disrupting either the 
formation or activity of the vRdRp. Finally, these mutations were introduced into the VSV 
genome and viral passages commenced. After multiple passages, compensatory mutations were 
found on the Phosphoprotein and the L-protein, which restored the vRdRp activity. This is 
indicative that these amino acids are pertinent towards creating an active vRdRp complex. While 
solving a structure of the vRdRp is the goal, the results presented in this study has significantly 
furthered our understanding of the interactions that are necessary for the formation of an active 
vRdRp. 
The third lens investigates how the vRdRp self-regulates its processivity. For the vRdRp 
to carry out its transcriptional chemistry, it first must access the RNA by opening the 
nucleocapsid. Thinking about this structurally and chemically, one can imagine a region in which 
the interactions between the nucleoprotein and the RNA are strong and/or weak. These 
strong/weak regions would have a significant impact on the ability of the polymerase to access 
the RNA and carry out transcription. This would mean that the processivity of the vRdRp would 
change based upon the sequence content of the genome. To validate this, the sequence content of 
the genome, and not the encoded protein content, was changed and the activity of the vRdRp was 
assessed. It was found that changing the sequence content could actively modulate the 
processivity of the vRdRp. Utilizing our structural knowledge of the nucleocapsid it was 
proposed that base stacking interactions, arising from the structural properties of the RNA in the 
nucleocapsid, might play a role in this stability. To assess this, a bioinformatics approach was 
used to analyze the sequence content of both the wt and altered gene sequences. In doing so, it 
was found that the ability of purine/pyrimidines to base stack with each other significantly 
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changed the properties of the sequence. Finally, to experimentally validate that 
purine/pyrimidine base stacking alters the stability of the nucleocapsid, we assessed the 
nucleocapsid containing either a purine (poly(rA)) or pyrimidine (poly(rU)) by a thermal shift 
assay. It was found that purines significantly increase the stability of the nucleocapsid, while 
pyrimidines decrease the stability. In doing so, we propose that it is the purine/pyrimidine base 
stacking content which can modulate the stability of the nucleocapsid. In changing this stability, 
it also changes the processivity of the vRdRp. This finding is particularly important in 
understanding how NSVs regulate protein production and various forms evolutionary 
constraints. The contents of this study could be directly applied to the development of vaccines 
and targeted antivirals towards the NSV family. 
This three-tiered approach has given a complete picture of the structure function 
relationships that guide the biological function of the nucleocapsid protein in VSV. A thorough 
understanding of these relationships has allowed for the design of a novel antiviral compound, 
the elucidation of important amino acids involved in viral RNA transcription, and a paradigm 
shifting approach of the understanding in how NSVs modulate viral RNA synthesis through the 
interaction of the genome with the nucleoprotein. This understanding of the basic science behind 
the driving forces of how the nucleocapsid is intimately involved in the viral replication life 
cycle, represents a shift in the understanding of its functional properties. These three studies 
represented in this work epitomize an interdisciplinary approach towards illuminating the basic 
chemical and structural principles that guide the biology of NSVs. The underlying theme of this 
work is the utilization of these techniques and how they can bring about a broader understanding 
of not only VSV, but towards the underlying mechanisms that control the NSV life cycle. In 
doing so, the knowledge gained in this dissertation can be directly applied towards more 
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pandemic pathogens, in the hope of bettering the human condition and life-span by preventing 
emergent diseases from taking hold and potentially saving lives. 
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Schema of the Baltimore classification system devised by David Baltimore, which groups viruses 
based on their method of replication. 
 
 
 
 
 
 
 
Figure 1.1 Baltimore Classification System 
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Life Expectancy and Published Protein Structures. A. A bar graph showing the average life 
expectancy increasing by nearly 5 years from 2000-2015. B. The number of deposited structures 
in the Protein Databank increasing every year since the early 1990’s. C. There is a strong 
correlation between Life Expectancy and the number of Protein Structures Deposited. While it is 
not causation, it speaks the importance of science. 
Figure 1.2 Life Expectancy and Published Protein structures. 
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Negative Strand RNA Virus Overview. A. Method of replication utilized by Negative Strand RNA 
Viruses. B. A succinct table of some commonly known Negative Strand RNA Viruses and their 
Family of classification. C. Cartoon drawing of Vesicular Stomatitis Virus used with permission. 
ViralZone: https://viralzone.expasy.org/21 SIB Swiss Institute of Bioinformatics.  
Figure 1.3 Negative Strand RNA Virus Overview 
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2 A POLYAMIDE INHIBITS REPLICATION OF VESICULAR STOMATITIS VIRUS 
BY TARGETING THE RNA IN THE NUCLEOCAPSID 
Copyright © American Society for Microbiology, [Journal of Virology, Volume 92, Issue 8, 
April 2018, e00146-18, DOI: 10.1128/JVI.00146-18] 
2.1 Abstract 
Polyamides have been shown to bind double-stranded DNA by complementing the 
curvature of the minor groove and forming various hydrogen bonds with DNA. Several 
polyamide molecules have been found to have potent antiviral activities against papillomavirus, 
a double-stranded DNA virus. By analogy, we reason that polyamides may also interact with the 
structured RNA bound in the nucleocapsid of a negative strand RNA virus. Vesicular stomatitis 
virus (VSV) was selected as a prototype virus to test this possibility since its genomic RNA 
encaspsidated in the nucleocapsid forms a structure resembling one strand of an A-form RNA 
duplex. One polyamide molecule, UMSL1011, was found to inhibit infection of VSV. To 
confirm that the polyamide targeted the nucleocapsid, a nucleocapsid-like particle (NLP) was 
incubated with UMSL1011. The encapsidated RNA in the polyamide treated NLP was protected 
from thermo-release and digestion by RNase A. UMSL1011 also inhibits viral RNA synthesis in 
the intracellular activity assay for the viral RNA-dependent RNA polymerase. The crystal 
structure revealed that UMSL1011 binds the structured RNA in the nucleocapsid. The 
conclusion of our studies is that the RNA in the nucleocapsid is a viable antiviral target of 
polyamides. Since the RNA structure in the nucleocapsid is similar in all negative strand RNA 
viruses, polyamides may be optimized to target the specific RNA genome of a negative strand 
RNA virus, such as respiratory syncytial virus and Ebola virus.  
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2.2 Introduction 
Many pathogenic viruses are negative strand RNA viruses (NSVs), such as respiratory 
syncytial virus (RSV), and parainfluenza viruses (e.g. PIV3), which cause severe infections in 
children. For instance, RSV accounts for up to 80% of hospitalization due to acute respiratory 
infections in children (77). Treatment options are limited and no effective vaccines are currently 
available, which creates an urgent unmet need for novel antiviral medications for respiratory 
illness in children and adults. Furthermore, deadlier NSVs include rabies virus and Ebola virus, 
for which no effective antiviral drugs are available (178-180). 
One common feature of all NSVs is that they encode their own RNA-dependent RNA 
polymerase (vRdRp) in the genome. During transcription/replication, the vRdRp must access the 
structured RNA genome sequestered in the nucleocapsid and will not recognize the free RNA 
genome as a template for RNA synthesis. This makes the nucleocapsid a prime target for broad 
antiviral therapies. The crystal structure of a nucleocapsid-like particle (NLP) was first solved for 
vesicular stomatitis virus (VSV)(89) revealing that the nucleocapsid protein (N) forms a polymer 
with extensive intermolecular interactions to package the genomic RNA (174). The N-protein 
has a deep cleft between its N-terminal and C-terminal lobes where the genomic RNA is 
sequestered (Figure 2.1A). When the genomic RNA is packaged in the nucleocapsid, it assumes 
a unique structure (Figure 2.1B). If we count the nucleotides from 5’ end to 3’ end, 9 nucleotides 
are covered by each N subunit. The bases of nucleotide 1 to 4 are stacked with the bases facing 
the exterior of the cleft, whereas bases of nucleotide 5 and nucleotides 7-9 are stacked with the 
bases facing the interior of the cleft. The base of nucleotide 6 does not stack with other bases. 
The base stacking of nucleotides 1-4 or 5,7-9 are curved. The orientation of the ribose and the 
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phosphate groups do not have a regular conformation either. The bases of VSV RNA are more 
parallel to each other in nucleotides 1-4, than 5, 7-9.  
One such class of drugs that have been shown to target nucleotide moieties are 
polyamides. Several polyamides have been developed as inhibitors of gene expression and other 
biological effectors that bind double stranded DNA (dsDNA) in a sequence-specific manner (58-
62, 181-183), and other polyamides have also been developed as broad-spectrum antivirals for 
papillomaviruses and polyomaviruses precisely because they do not show sequence-specific 
binding properties (63-65, 184-188). Others have also since discovered nonspecific polyamide 
effects (189, 190). Polyamides have not been cytotoxic to HeLa (191) or other mammalian cells 
in these reports, in one case showing SI values of at least 2000 before reaching compound 
solubility limits (65). Within the G nucleotides of a DNA helix, imidazole (Im) moieties of 
polyamides can act as an H-bond acceptor of one hydrogen from the exocyclic NH2 as predicted 
by Dickerson (192). Furthermore, pyrrole (Py) residues and β-alanine residues (β) typically bind 
to A, T, and C through H-bond donation from amide bond NH groups to acceptor N or O groups 
in the minor groove. 
Since polyamides have been shown to target structured nucleotide moieties and form 
hydrogen bonds, such as the structure found in the nucleocapsid-bound RNA of VSV, we tested 
a group of polyamides for possible antiviral activities against VSV (see Table 2.1). One 
molecule, UMSL1011 (Figure 2.2), was found to inhibit VSV replication. Further experiments 
found that UMSL1011 could protect the encapsidated RNA from thermo-release, digestion by 
RNase A, and inhibit vRdRp mRNA synthesis. Finally, the crystal structure of UMSL1011 
bound to the VSV NLP was solved and it was found to directly target the encapsidated RNA. 
Our results indicate a novel use of polyamides and can potentially be developed as antiviral 
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drugs against other NSVs which cause widespread diseases. This opens a new avenue for drug 
discovery to effectively control NSV infection. 
2.3 Results 
2.3.1 Antiviral Screen 
A plaque assay for VSV infection was set-up for antiviral screens. Six different 
polyamide compounds (Table 2.1) prepared previously were included. When inhibitor solutions 
at 20 μg/mL (130 μM) concentration of polyamides in 1% DMSO were added, UMSL1011 
inhibited VSV infection (Figure 2.3). This result confirmed that a polyamide compound could 
inhibit infection by VSV. The antiviral activity by UMSL1011 is specific because other 
polyamide compounds did not inhibit VSV infection at this concentration. Inhibition of VSV 
infection by UMSL1011 was repeated with different concentrations of UMSL1011 (Figure 2.3). 
At <10 µg/mL (<65 μM) , UMSL1011 inhibits plaque formation by VSV infection.  
2.3.2 Melting Curve Analysis 
In order to verify that UMSL1011 is targeting the nucleocapsid, Differential Scanning 
Fluorimetry (or a Thermal Shift Assay (TSA)) was carried out. More specifically we wanted to 
test if UMSL1011 could delay the thermal release of the RNA from the NLP.  Two different 
fluorescent dyes were selected to target the encapsidated RNA and protein, respectively. For 
RNA, SYBR Safe was used to stain DNA/RNA in electrophoresis gels, because it works by 
intercalating DNA/RNA and then fluorescing. Since the bases of the RNA inside NLP are 
stacked, and the local RNA concentration is high inside the NLP as well, clear fluorescence was 
observed when SYBR Safe was incubated with NLP (Figure 2.4). To approximate the 
temperature when the RNA is dissociated from the NLP, we call this Tfree, the 1st derivative 
graph was calculated for the rate of fluorescence changes. Most importantly, the peak in the 2nd 
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derivative of the melt-curve defines the temperature point at which the rate change is at the 
maximum.  We name this temperature as Tfree to indicate the RNA release from the NLP. To 
confirm our findings, SYPRO Orange was used to detect protein melting. The melting of the 
protein in the NLP is correlated with the release of encapsidated RNA because RNA can 
stabilize the protein in NLP (173, 174). We have previously observed RNA release from NLP 
when temperature was increased (173). Since the melting of the protein roughly follows the 
release of the RNA, as defined by Tfree, ΔTfree can be used to investigate the stability of the 
encapsidated RNA in the NLP.      
Using this assay, it was shown that when 200 μg/mL (1.3 mM) of UMSL1011 was 
incubated with NLP, Tfree was shifted upward by ~2 °C (68.86 vs 66.82 °C) (Figure 2.4). We 
interpreted this observation of Tfree shift as UMSL1011 binding and stabilizing the RNA in 
NLP. A shift of 2 °C in Tm is typical when an organic compound binds a protein in vitro (193). 
On the other hand, Tfree was only shifted by ~0.3 °C from an inactive polyamide molecule 
UMSL1013 (Figure 2.4), suggesting that UMSL1013 does not stabilize the encapsidated RNA 
in the NLP. Interestingly, UMSL1011 has a slight effect on protein stability, showing a -0.9 °C 
shift when compared to the DMSO control (69.86 °C w/ UMSL1011, and 70.75 °C w/DMSO 
alone) (red lines in Figure 2.4). Furthermore, the unfolding of the protein begins after RNA is 
released from the NLP in all cases.  
2.3.3 RNA protection 
To further verify our melting curve analysis findings, RNA from NLP was exacted by 
phenol extraction. The freed RNA was subjected to RNase A digestion in the absence and 
presence of 200 μg/mL (1.3 mM) UMSL1011 in 1% DMSO. There was no protection of the 
freed RNA from RNase A digestion by UMSL1011 (Figure 2.5A). This observation is 
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consistent with our hypothesis that UMSL1011 could only bind the structured RNA in NLP. 
Digestion of RNA encapsidated by the NLP was also carried out. Previously, we have shown 
that RNA inside NLP could be digested by RNase A (173). In this case, digestion of RNA in the 
NLP was protected by UMSL1011 (Figure 2.5B), whereas the inactive UMSL1013 allowed for 
RNA digestion (Figure 2.5B).  
2.3.4 Evaluation of cytotoxicity  
Previous studies showed that UMSL1011 and its analogs did not show cytotoxicity up to 
200 µM (65). UMSL1011 were evaluated for cytotoxicity by MTT assays using CellTiter 96® 
from Promega. It was found that even up to 650 μM of UMSL1011, it exhibited very little 
cytotoxicity (Figure 2.6C). This is indicative of a low probability of off-target effects and is 
consistent with previous data. 
2.3.5 Minigenome Assay 
  To further test the specificity of UMSL1011 to inhibit VSV viral RNA synthesis, a 
commonly used minigenome assay/RT-qPCR was adapted to quantify mRNA transcripts (194-
197). The N gene with three stop codons after the initiation Met codon was used as the reporter 
gene to encourage no bias. With this assay, UMSL1011 was shown to inhibit viral synthesis of 
mRNA for the reporter gene. The raw CT values for the qPCR assay are shown in Figure 2.6A 
and a normalized ΔCT value are shown in Figure 2.6B. The ΔCT was calculated by comparing 
the house keeping gene, β-actin, to the CT value of the mRNA. This was then normalized to the 
Mock ΔCT values allowing the calculation of a relative % inhibition of transcription for 
UMSL1011. Compared to the DMSO control transfection, UMSL1011 at 20 µg/mL (130 μM ) 
inhibited transcription of mRNA by 54.5%, whereas the DMSO compared to the Mock about 
8.2%. It is worth noting that the p-value of >0.05 for comparing the Mock to the DMSO control 
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was not statistically significant. On the other hand, the p-value for the UMSL1011 sample 
compared to the Mock/DMSO control was p<0.001, showing a high level of confidence in 
statistical significance. Also, to corroborate our analysis with the well known 2-ΔΔCT analysis 
Appendix A.1 show these values. These further confirm the pattern that is seen with our 
minigenome analysis.   
2.3.6 Crystal Structure 
In order to fully define the interactions of UMSL1011 with the structured RNA in the 
NLP, the crystal structure of UMSL1011 bound NLP was determined by X-ray crystallography 
(see Table 2.2 for statistics). The electron density corresponding to Py-3, Im-4, γ-5, and Py-6 of 
UMSL1011 (see Table 2.1 and Figure 2.2) was found in the NLP (Figure 2.7A). Due to 
resolution limitations and randomly encapsidated RNA when the NLP was purified from E. coli, 
the RNA was first modeled as a poly-U chain, as done previously (89, 173). In total UMSL1011 
forms seven hydrogen bonds with the RNA and two hydrogen bonds with the N-protein (Figure 
2.7B). The electrostatic surface of UMSL1011 based on APBS calculations confirmed the 
hydrogen bond potential of each UMSL1011 group (Figure 2.7C). This confirmed that the 
methyl group in Im-4 is polarized so their hydrogens may form hydrogen bonds with a proton 
acceptor, as found in (198-200). The amide nitrogen and the carbonyl group directly preceding 
the Im-4 each make a single hydrogen bond with the base of nucleotide 9. The three polarized 
methyl hydrogens coming off the Im-4 each form a hydrogen bond with the two riboses of 
nucleotide 7 and 8, and the phosphate between nucleotides 7 and 8. Im-4 also participates in 
weak π-π stacking with the base of nucleotide 9, further anchoring the Im-4 in place. 
Furthermore, the amide nitrogen and carbonyl group after Py-3 each forms a hydrogen bond with 
the base on nucleotide 3 and 4, respectively. The carbonyl group directly preceding Py-6 forms a 
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hydrogen bond with Arg-312, seemingly anchoring the γ-5 turn in place, and the methyl group 
on Py-6 interacts with the backbone carbonyl on Gln-318. The side of UMSL1011 that interacts 
with RNA is more positively charged, whereas the opposite side is mostly negatively charged. 
Unlike other polyamide interactions that would normally target the minor groove of DNA (201), 
UMSL1011 stretches across the structured RNA by making contacts with both the bases and the 
backbone (Figure 2.7D). Interestingly, UMSL1011 fits in a pocket created by the interface 
between two N subunits and the encapsidated RNA (Figure 2.7A).  
For the genomic RNA in the VSV nucleocapsid, there could be any nucleotide sequence 
in each position that interacts with UMSL1011. To define the optimal sequence for binding with 
UMSL1011, we modeled each base at the RNA position in the UMSL1011-NLP complex. The 
possible hydrogen bonds between UMSL1011 and NLP are summarized in Table 2.3. This 
model suggests that 5’AXXCUXXGG3’ may be the preferred sequence motif to bind with 
UMSL1011. The specific base is designated for that nucleotide position based on optimal 
hydrogen bond formation with the interacting moiety of UMSL1011. Survey of the genomic 
sequences found that there are 18 of this motif in the negative strand and 6 in the plus strand, 
which represent all potential binding sites for UMSL1011. 
To investigate whether UMSL1011 induces any structural changes, we aligned the A 
chain of the UMSL1011 bound structure with the A chain of PDB 2GIC—the original structure 
of the nucleocapsid. These crystals were grown under the same conditions as 2GIC. There is 
almost no change in the N subunit structure where UMSL1011 is bound (Figure 2.8A). 
However, globally the overall NLP ring has tightened significantly. The diameter of the original 
NLP is 46.6 Å, measured from the C-terminus to C-terminus of two opposite N subunits in the 
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ring, whereas the UMSL1011 bound NLP has a diameter of 44.3 Å (Figure 2.8B). This ring 
tightening of 2.3 Å can be corroborated with our TSA and RNA protection data.  
2.4 Discussion 
Many pathogens are negative strand RNA viruses, including rabies virus, respiratory 
syncytial virus and Ebola virus. Currently, there are no antiviral drugs targeting viral RNA 
synthesis by its unique viral RNA-dependent RNA polymerase (vRdRp). A large body of 
structural studies on the nucleocapsid of NSVs revealed a common mechanism of NSV viral 
RNA synthesis (202). During viral transcription and replication, vRdRp recognizes the 
nucleocapsid and gains access to the genomic RNA sequestered in the nucleocapsid to use it as 
the template. vRdRp must induce conformational changes in the nucleocapsid to release the 
genomic RNA for initiation and elongation during viral RNA synthesis. This provides a unique 
opportunity for antiviral inhibitors. Since the nucleocapsid is the template for viral RNA 
synthesis, viral replication will be blocked by a compound that binds the nucleocapsid. 
By plaque assays, six different polyamide compounds were screened for inhibitory 
activities against VSV infection (Figure 2.3). One compound, UMSL1011, was found to inhibit 
VSV infection. UMSL1011 was further confirmed to specifically inhibit viral RNA synthesis 
using an intracellular vRdRp minigenome assay (Figure 2.6). It is noted that UMSL1011 
reduced viral plaques by about 50% at concentrations between 65-130 µM.. This is further 
corrorborated by the minigenome assay, which shows a reduction of 54.5% in the mRNA levels 
synthesized by the vRdRp when 130 µM of UMSL1011 was added. This would indicate that 
UMSL1011 could not inhibit viral RNA synthesis very efficiently in this concentration range, 
allowing for a small amount of virus to continue through replication. Furthermore, the reduction 
in activity of viral RNA synthesis is not due to off target effects of UMSL1011. Previously, it 
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was shown that UMSL1011 had little effect on the gene regulation in the apoptotic, dna repair, 
and cell cycle pathways (184).While this is important to note, it allows one to use UMSL1011 as 
an existing model to design more active polyamide based inhibitors. 
 To clearly define the target and reveal the mechanism of UMSL1011 inhibition, a 
melting curve and RNA protection studies were carried out on recombinantly expressed NLP. 
Due to the possible sequence specific manner in which UMSL1011 interacts with the NLP and to 
account for the randomly encapsidated RNA from E. coli, the concentration of UMSL1011 was 
increased for all in vitro experiments on the NLP. By systematically increasing the temperature, 
structural changes are expected to occur in the nucleocapsid. Two fluorescent dyes were used to 
monitor the structural changes. One dye, SYBR Safe, intercalates between stacked bases of 
RNA. At the beginning, the fluorescence of SYBR Safe was high when incubated with NLP, 
suggesting tight binding to NLP. When the temperature continued to increase, the fluorescence 
of SYBR Safe started to drop indicating reduction in RNA binding, but the fluorescence of 
SYPRO Orange, the other dye we used to monitor protein unfolding, did not change very much. 
At a critical temperature, the fluorescence from the RNA released began to increase, indicating 
that that the RNA had already been released. To define a more common point after RNA release, 
the 2nd derivative was utilized and named Tfree. The observation of thermo-release of RNA 
from NLP was consistent with our previous studies of RNA digestion (173). However, we 
interpreted it as that the RNA sequestered in NLP was thermally released and named this 
temperature as Tfree. Past this temperature, the fluorescence of SYPRO Orange began to 
increase rapidly and a second Tm was observed, suggesting unfolding of the nucleocapsid 
protein. This indicates that the encapsidated RNA can stabilize NLP. When the melting curve 
measurement was repeated in the presence of UMSL1011, Tfree was increased by ~2°C (Figure 
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2.4), indicating binding of UMSL1011 stabilizes NLP and prevents thermo-release of 
sequestered RNA. When an inactive polyamide UMSL1013 was added, Tfree was not increased. 
Subsequently, an RNA protection assay was carried out to confirm that UMSL1011 binds only 
the RNA structure in NLP (Figure 2.5). If UMSL1011 was able to interact with the unstructured 
RNA extracted from the NLP, we would have seen distinct fragmentation of the RNA strand 
after RNase digestion. However, when the RNA in NLP was extracted, it was completely 
digested by RNase A in the absence or presence of UMSL1011, suggesting no interactions 
between free RNA and UMSL1011. On the other hand, the RNA in NLP may be digested by 
RNase A when the temperature was raised to release RNA (173). When NLP was incubated with 
UMSL1011, the RNA in NLP was protected from RNase A digestion, indicating that 
UMSL1011 binds the RNA in NLP, further indicating that UMSL1011 stablizes the NLP.  The 
slight shift in the migration pattern is due to slight nibbling of exposed ends of the RNA by 
RNase. At the same time, the inactive UMSL1013 did not protect the RNA in NLP from RNase 
A digestion.   The in vitro studies further argue that the polyamide UMSL1011 binds the RNA in 
the nucleocapsid to prevent it from serving as a template for RNA synthesis by vRdRp. 
The co-crystal structure of UMSL1011 bound to the NLP further validates the in vitro 
and biochemical results. Importantly UMSL1011 was found to interact with both the structured 
encapsidated RNA and the nucleocapsid protein (Figure 2.7). UMSL1011 binds the NLP in a 
manner not previously observed in polyamides. This unique binding pattern could be optimized 
to target more pathogenic NSVs. Not only is there an intricate hydrogen bonding network 
between UMSL1011 and the RNA/protein (Figure 2.7B), but also binding UMSL1011 effects 
the NLP globally causing a tightening of the NLP ring by 2.3 Å (Figure 2.8B). Furthermore, a 
preferred UMSL1011 binding motif could be identified in the genomic RNA sequence (Table 
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2.3). Taking all into account, the inhibition of viral RNA synthesis by UMSL1011 could be a 
two-fold process. The tightening of the nucleocapsid would make it harder for the polymerase to 
access the encapsidated genome, slowing the polymerase down or causing the complex to fall 
apart completely. Furthermore, UMSL1011 directly interacts with the RNA causing an 
impassable blockage in the path of the polymerase complex.    
To our knowledge, this is the first time that the encapsulated genome of an NSV has been 
directly targeted by an antiviral compound. Furthermore, this is the first evidence of a polyamide 
targeting and inhibiting the RNA synthesis of an NSV. Other NSVs exhibit similar RNA 
structures with stacked bases found inside the nucleocapsid, including rabies virus, respiratory 
syncytial virus and measles virus (85, 86, 203). Such structures may also be expected in other 
NSVs, including Ebola virus and Hantavirus because the structure of their nucleocapsid proteins 
and the capsid assembly are very similar (204-206). While UMSL1011 may be specific for VSV, 
it is possible that other polyamides can target other NSVs in a specific manner and would be 
subject of future studies. Our proof-of-concept studies on nucleocapsid binding and inhibition of 
VSV infection by UMSL1011 set a precedent for design of polyamide molecules as antiviral 
agents against other NSVs. 
2.5 Methods 
2.5.1 Antiviral Screen  
VSV (Indiana strain) stocks were prepared in BHK-21 cells (173). Monolayer HeLa cells were 
cultured in DMEM supplemented with 10% FBS, and grown to full confluence in 12-well plates. 
After washing with DPBS, VSV was dispensed over the cells and allowed to be absorbed for one 
hour in 37 °C, 5% CO2. The excess virus inoculum was washed away and the cells were overlaid 
with DMEM containing 0.8% agarose. After 48 hrs, the cells were fixed with 4% formaldehyde 
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and the agarose overlay was removed. The plate was stained with 0.1% crystal violet, and the 
plaques were counted.  
2.5.2 Thermal Shift Assay  
Prior to carrying out the TSA, the isolation of recombinantly expressed NLP was purified 
according to the protocol as previously established by our lab (144). All NLPs were checked by 
UV/Vis to verify the 260/280, ensuring RNA encapsidation, and SDS-page to verify protein 
purity. To test the efficacy of the compound in the Thermal Shift Assay, a final concentration of 
200 μg/mL (1.3 mM) of UMSL1011 or UMSL1013, which corresponds to a final concentration 
of 1% DMSO, was incubated with 25 μM (1.2 mg/mL) of NLP. To ensure binding to the NLP 
three rounds of incubation at 42°C for 15 minutes with subsequent incubation on ice for 15 
minutes each were carried out—this was also carried out with the DMSO control. Stocks 
solutions 100X were prepared in the reaction buffer (50 mM Tris pH 7.5, 300 mM NaCl) for the 
SYBR Safe and SYPRO Orange dyes. Each TSA reaction was carried out in 20 μL volumes 
which contained final concentrations of 20 μM of NLP, 1% DMSO or 180 μg/mL of 
UMSL1011/1013 dissolved in DMSO, and a 10X concentration of the dyes. The 20μL reactions 
were prepared in triplicates and placed into a MicroAmp Fast 96-well plate. A QuantStudio3 was 
used to carry out the TSA with a gradient of 0.025 °C/s from 25-95 °C. The Savitzky-Golay 
method was used to smooth the raw data and then 1st and 2nd derivative analysis was done to 
identify the Tm and Tfree, respectively. 
2.5.3 RNA protection  
RNA was extracted using Trizol reagent from Ambion by Life Technologies following the 
manufacturers protocol. After RNA extraction, the RNA was subjected to RNase treatment (final 
concentration of 15 μg/mL) both with 1% DMSO and 200 μg/mL (1.3 mM) of UMSL1011 for 
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30 mins and 1 hour respectively. Samples were then loaded on a 2% agarose gel and visualized 
with SYBR Safe. The RNA encapsidated by the NLP was digested with 1 mg/mL of RNase for 
15 or 30 minutes at 42 °C. Prior to RNase digestion, 200 μg/mL of compounds/1% DMSO was 
added to the NLP and the cycling of temperature was carried out in the same manner as the TSA. 
Each reaction was quenched by using the Trizol reagent and subsequent extraction of the RNA. 
The samples were then loaded on a 2% agarose gel containing SYBR Safe and further visualized. 
Gel Analyzer 2010a was used to quantify the intensity of the bands on the gels, for further 
analysis.  
2.5.4 Evaluation of Cytotoxicity  
HeLa cells were grown to confluence in 100 mL of DMEM supplemented with 10% Fetal 
Bovine Serum (FBS) in 96-well. MTT assays were carried out following the protocol from the 
manufacturer of CellTiter 96® (Promega, Madison, Wisconsin, USA). 
2.5.5 Minigenome Assay  
The minigenome assay was designed and carried out as described previously (194-197). 
We constructed the minigenome to transcribe a non-translatable N gene by adding three stop 
codons to the beginning of the gene. The minigenome and the helper plasmids were co-
transfected and either compound (final concentration 20 μg/mL (130 μM)) or 1% DMSO was 
added to the media. RNA was extracted using the RNeasy RNA Extraction Kit (Qiagen), using 
the manufacturer’s protocols 48 hours post transfection. Immediately after RNA extraction, 
reverse transcription was carried out to make the cDNA using the primers 5’-
CCAGATCGTTCGAGTCGTTTTTTTTTTTTTTTTTCATTTGTCAAATTCTGACTTAG-3’, 
for the N mRNA transcripts, and 5’-AGCACTGTGTTGGCGTACAG-3’, for β-actin, using M-
MLV reverse transcriptase from Invitrogen following the manufacturer’s protocol. After cDNA 
56 
synthesis, qPCR was carried out with PowerUp SYBR Green Mastermix following the 
manufacturer’s instructions for concentrations and cycling protocols. In short, 10 ng of cDNA 
was used as a template and 500 nM of both primers 5’-GTTGAATGGCTCGGATGGTTC-3’ 
and 5’-CCAGATCGTTCGAGTCGT-3’ for the mRNA transcript of N and 5’-
AGAGCTACGAGCTGCCTGAC-3’ and 5’-AGCACTGTGTTGGCGTACAG-3’ for the β-actin 
transcript. 40 cycles of PCR were carried out and a subsequent melting curve to check for 
transcript homogeneity. The primer only (polymerase plus primers), the no primer (template plus 
polymerase), and the no reverse transcriptase reaction showed no discernable CT values when 
doing the experiment—the fluorescence was under the threshold to discern a CT value. The 
background fluorescence is taken into account when setting the baseline for the qPCR reactions, 
utilizing all of the controls as well, thus only using concentrations of the template yielding CT 
values greater than 15 are used—so one can get an accurate baseline to set the CT value.  Data 
were then analyzed using the ΔCT method for relative mRNA quantitation. 
2.5.6 Structure  
Crystallization was carried out as previously described with minor modifications prior to 
crystallization to facilitate UMSL1011 binding (89). Otherwise, everything else was kept as 
previously. Prior to crystallization, UMSL1011 (1 mg/mL (6.5 mM)) was incubated with the 
NLP in the same manner as the thermal shift assay. In short, three rounds of incubation at 42 °C 
for 15 minutes followed by subsequent incubation on ice for 15 minutes was carried out. 
Hanging drops were set up immediately after incubation and crystals appeared after 7-10 days. 
Data was collected at the Advanced Photon Source on SER-CAT 22-ID with an oscillation angle 
of 0.3 °. Data was processed with the XDS-package and molecular replacement was carried out 
(PDB code: 2GIC as a search model) using maximum-likelihood procedures in PHASER with 
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the Phenix Suite (207, 208). The structure was then refined using phenix.refine in the Phenix 
Suite and model building/ligand placement was done in COOT (208, 209). The restraints for the 
UMSL1011 fragment were generated using eLBOW in the Phenix Suite from a SMILES string 
(208). All the figures were prepared with PyMol (210). Electrostatic surface potentials of 
UMSL1011 were generated using APBS and visualized using UCSF Chimera as described 
previously (211, 212).     
2.5.7 Chemistry  
Polyamides were synthesized on ABI433A or CSBio 136XT peptide synthesizers using Boc 
methodology and extensive incorporation of dimer building blocks as previously described (185, 
213-218). Boc-β-alanine-PAM resin was obtained from Peptides International and building 
blocks were from A Chemtek or were synthesized in-house.  Dimethylamine-free DMF was from 
ABI (now Fisher).  UMSL1028, UMSL1011, UMSL1055, and UMSL2115 were synthesized, 
purified and described as previously (65, 184, 216). Compounds were cleaved off the resin with 
N,N-diaminopropylamine, leading to Dp derivatives, or with bis(aminopropyl)methylamine, 
leading to Ta derivatives.  Preparative reverse phase chromatography was carried out on a 
Phenomenex C18 Luna column in MeOH/water with 0.1% TFA, and the TFA salts were isolated 
by lyophilization.  All compounds were analyzed for purity by two orthogonal HPLC and 
HPLC/MS methods: Reverse Phase C12 on a Phenomenex Jupiter column in an MeCN/water 
gradient (HPLC/MS) and a Phenomenex Synergi Polar-RP column with ammonium formate 
running buffer for the orthoganonal HPLC.  Exact masses were determined by ESI, and 500 
MHz or 600 MHz 1H NMR spectra were obtained.  Typically, 13C and various 2-D NMR 
spectra were also obtained. All chemical characterization are present in the Supplemental 
Materials. 
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RNA Structure in VSV NLP. (A) Ribbon and stick drawings of VSV N in complex with RNA. The 
N-terminal lobe is shown as ribbons in green, and C-terminal lobe in yellow. The N-terminal 
arm and the C-terminal loop elements are labeled. RNA structure in the center is shown as a 
stick model. (B) Cartoon diagram of a single subunit in the VSV NLP from the perspective of the 
N-lobe. This shows the RNA base-stacking that occurs within the NLP. All drawings were 
created with PyMol (210). 
 
 
 
 
 
 
 
 
 
Figure 2.1 RNA Structure in VSV NLP. 
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Table 2.1 Polyamides used in antiviral screen, with their building blocks defined 
Compound N-terminus 2 3 4 5 6 7 8 9 10 C-terminus Activity 
UMSL1011 dIm Py Py Im γ Py Py Py Py β Dp active 
UMSL1013# dIm Py Py Py γ Py Py Im Py β Dp inactive 
UMSL1028§ dIm Py Py β Py Py Py y     
(cont.) Py Py β Py Py Py Py β Ta   inactive 
UMSL1055 dIm Im Py Py γ Py Im β Py β Dp inactive 
UMSL2115 fPy* Im β Im γ Py Py β Py β Ta inactive 
UMSL2082 dIm Im Py γ Py Py Py β - - Ta inactive 
 
dIm indicates an N-terminal n-methyl imidazole lacking an amino group (des-amino-N-
methylimidazole-2-carboxylate). Py is derived from 4-amino-2-carboxy-N-methylpyrrole; Im is 
derived from 4-amino-2-carboxy-N-methylimidazole. β is derived from β-alanine; γ from γ-
aminobutyric acid. Dp is derived from N,N-dimethylpropylamine; Ta from 
bis(aminopropyl)methylamine. #was previously reported and is inactive against HPV(22, 23). 
§UMSL1028 is a 16-residue polyamide active against HPV16, 18 and 31. *fPy is derived from 4-
formamido-N-methylpyrrole-2-carboxylate. 
 
 
 
 
 
 
 
 
 
60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Structure of Polyamides Used. A) The cation of UMSL1011 as isolated as a tris(TFA) salt.  (B) 
The cation of UMSL1013 as isolated as a tris(TFA) salt.  
 
 
 
 
 
 
Figure 2.2 Structure of Polyamides Used 
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VSV plaque assays. (A) The initial screen of six polyamide compounds (20 μg/mL). Controls of 
uninfected cell, medium only and 1% DMSO were included. The compound names were labeled 
for each well. (B) After virus adsorption for 1 hr, UMSL1011 at different concentrations was 
added to the agarose overlap. DMSO was used as the solvent negative control. Experiments 
were done in triplets and the plaques were counted at 18 hr postinfection. 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 VSV plaque assays. 
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Melting curve analysis. VSV NLP was incubated with 200 μg/mL (1.3 mM) USML1011 (right 
column), 200 μg/mL  UMSL1013 (middle column), and in 1% DMSO (left column). NLP was at a 
concentration of 1.2 mg/mL in 50 mM Tris, 300 mM NaCl, pH 7.5. Both SYBR Safe and SYPRO 
Orange were added to the NLP sample (Blue and Red trace, respectively). The temperature was 
scanned at 0.025 °C/s in QuantStudio 3 instrument. The first derivative and the second 
derivative graphs are presented. Tfree (= 68.9 °C) (equivalent to Tm) is determined from the 
second derivative graph. The left column shows the results from the same experiment and 
presentation as the right column, except that NLP was incubated with 1% DMSO. Tfree (= 66.8 
°C) is determined from the second derivative graph. To have a negative control, the Tfree 
measurements were repeated with an inactive compound UMSL1013 (central column). Tfree was 
relatively the same in comparison with DMSO control. All errors are shown as the standard 
deviation. 
 
 
 
 
Figure 2.4 Melting curve analysis. 
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RNA protection study. (A) RNA freed from NLP (Lane 2) was incubated with 15 μg/mL RNase A 
with (Lanes 3 and 4) and without (Lanes 5 and 6) 200 µg/mL (1.3 mM) UMSL1011 at 22 °C for 
30 (Lane 2 and 4) and 60 min (Lane 3 and 5), respectively. RNA markers (Lane 1) are included. 
(B) A bar graph quantifying the drop in intensity of each band in the gels shown in panels in C 
and D. Both +/-UMSL1011 and +/-UMSL1013 are shown compared to each undigested control, 
which is set at 100%. The program GelAnalyzer 2010a was used to quantify the brightness and 
overall peak area of each gel and normalized on a percentage based on the control. (C) NLP 
was incubated with 1 mg/mL RNase A at 42 °C without (Lanes 2-4) and with (Lanes 5-7) 200 
µg/mL (1.3 mM) UMSL1011. Lane 2 and 5 were 30 min digestion, and Lane 3 and 6, 15 min, 
respectively. Lane 4 and 7 had no RNase A. Lane 1 is RNA markers (200 b as the lowest band vs 
90 b RNA from NLP). (D) A control study with an inactive compound. 200 µg/mL UMSL1013 
(Lanes 4-6) was incubated with NLP (Lane 4, 15 min/Lane 5, 30 min). Lane 6 has no RNase A. 
Lanes 1-3 corresponds to the same reactions in the presence of 1% DMSO. 
 
 
Figure 2.5 RNA protection study.  
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Intracellular vRdRp assays and Cytotoxicity Study. (A) Raw CT values of mRNA transcripts from 
the minigenome assay and reporter gene, β-actin. Each CT value is taken as an average of three 
qPCR reactions and error bars represent the standard deviation. (B) Normalized ΔCT values to 
the Mock, set as 1. Each ΔCT was calculated by subtracting the experimental CT value to its 
subsequent β-actin CT and the error bars represent the standard deviation. This shows a 
significant decrease in mRNA transcripts when UMSL1011 is added. *** indicates a p < 0.001 
and ns indicated a p > 0.05 (C) Cytotoxicity studies. Monolayers of HeLa cells were incubated 
with 130 µM and 650 µM UMSL1011, respectively, for 25 hr. 1% DMSO was used as the solvent 
control. Cell viability was measured by MTT assays. Experiments were carried out in triplets 
and error bars representing the standard deviation. 
 
 
 
 
 
Figure 2.6 Intracellular vRdRp assays and Cytotoxicity Study 
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Table 2.2 Crystallographic Statistics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Wavelength 1 
Resolution range 45.39  - 3.46 (3.584  - 3.46) 
Space group P 2 21 21 
Unit cell 75.48 165.48 234.46 90 90 90 
Total reflections 168290 (16809) 
Unique reflections 38347 (3334) 
Multiplicity 4.4 (4.4) 
Completeness (%) 92.22 (86.26) 
Mean I/sigma(I) 6.79 (2.70) 
Wilson B-factor 100.3 
R-merge 0.1526 (0.6546) 
R-meas 0.1718 (0.7406) 
R-pim 0.07654 (0.3363) 
CC1/2 0.99 (0.742) 
CC* 0.997 (0.923) 
Reflections used in refinement 36198 (3334) 
Reflections used for R-free 1999 (184) 
R-work 0.2655 (0.3160) 
R-free 0.3107 (0.3572) 
CC(work) 0.912 (0.837) 
CC(free) 0.868 (0.775) 
Number of non-hydrogen 
atoms 17466 
  macromolecules 17417 
  ligands 49 
Protein residues 2086 
RMS(bonds) 0.003 
RMS(angles) 0.76 
Ramachandran favoured (%) 86.09 
Ramachandran allowed (%) 9.71 
Ramachandran outliers (%) 4.2 
Rotamer outliers (%) 10.07 
Clashscore 21.47 
Average B-factor 121.78 
  macromolecules 121.77 
  ligands 124.71 
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Crystal Structure of UMSL1011 bound to the NLP. A) 2mFo-dFc map (shown in blue) at 1 sigma 
of UMSL1011 (shown in green) bound to the NLP. The magenta sticks are nearby amino acids of 
the NLP, while the RNA is modeled in cyan. The transparent surface reconstruction shows the 
pocket for which UMSL1011 binds. (B) Hydrogen bonds made by UMSL1011 (shown in green) 
to both the encapsidated RNA (cyan) and the protein (magenta). (C) Electrostatic surface 
potential of UMSL1011 calculated by APBS and visualized in Chimera . The colored bar below 
shows the relative charge with red being electron dense and blue being electron deficient. (D) A 
two-dimensional cartoon outlining the hydrogen bonds between UMSL1011 and the 
RNA(polyrU)/protein. Protein contacts are shown with Gln318 amide carbonyl backbone, and 
the Nε of Arg312. 
 
 
 
 
 
Figure 2.7 Crystal Structure of UMSL 1011 bound to the NLP.  
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Global ring tightening of the NLP. (A) Overlay of 2GIC and UMSL1011 bound crystal structure. 
UMSL1011 is shown in green, while like previously, the magenta and cyan colors represent the 
protein and RNA, respectively. The 2GIC structure is colored yellow. There is little to no 
structural differences in the local area where UMSL1011 binds. (B) A reconstruction of the NLP 
ring. On the left-hand side is 2GIC (in yellow) and on the right-hand side is UMSL1011 
structure (in cyan). An overall, global tightening of the ring by 2.3 Å is observed when 
measuring the inner diameter from E-chain to E-chain, corresponding to the largest change in 
the ring diameter.   
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8 Global ring tightening of the NLP.  
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Table 2.3 UMSL1011 and RNA interactions based on Nucleotide Sequence 
 
 
In the UMSL1011-NLP structure, each base was modeled (A, G, U, and C) at each nucleotide 
position and all possible hydrogen bonds were examined. The nucleotide position is numbered 
for each row, and each moiety of UMSL1011 is for each column. The interactions of each moiety 
of UMSL1011with the respective base or the backbone are placed in each grid. The larger letters 
indicate possible selectivity for each nucleotide derived from optimal interactions, and the box 
highlighted in orange indicates interaction with the sugar/phosphate backbone. 
 
 
 
 
  
  Carbonyl-3  Amide (N)-3 Im-4 (methyl) Carbonyl-4  Amide (N)-4 γ-5 Carbonyl-6  Amide (N)-6 
5             A,C A 
6                 
7     Ribose-P           
8     Ribose-P   A,G,C       
9       U,A,C U,G       
1                 
2                 
3   U,A,G             
4 U,G G             
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3 MUTATIONS IN THE NUCLEOCAPSID PROTEIN WERE COMPLEMENTED BY 
MUTATIONS IN THE L-PROTEIN TO RESTORE VIRAL RNA SYNTHESIS 
Copyright © American Society for Microbiology, [Journal of Virology, Volume 92, Issue 22, 
November 2018, e01417-18, DOI: 10.1128/JVI.01417-18] 
3.1 Abstract 
During viral RNA synthesis by the viral RNA-dependent RNA polymerase (vRdRp) of 
vesicular stomatitis virus, the sequestered RNA genome must be released from the nucleocapsid 
in order to serve as the template. Unveiling the sequestered RNA by interactions of vRdRp-
proteins, the large subunit (L) and the phosphoprotein (P), with the nucleocapsid protein (N) 
must not disrupt the nucleocapsid assembly. We noticed that a flexible structural motif composed 
of an α-helix and a loop in the N-protein may act as the access gate to the sequestered RNA. This 
suggests that local conformational changes in this structural motif may be induced by 
interactions with the polymerase to unveil the sequestered RNA, without disrupting the 
nucleocapsid assembly. Mutations of several residues in this structural motif, Glu169, Phe171 
and Leu174, to Ala resulted in loss of viral RNA synthesis in a minigenome assay. After 
implementing these mutations in the viral genome, mutant viruses were recovered by reverse 
genetics and serial passages. Sequencing the genomes of the mutant viruses revealed that 
compensatory mutations in L, P and N were required to restore the viral viability. Corresponding 
mutations were introduced in L, P and N, and their complementarity to the N mutations was 
confirmed by the minigenome assay. Introduction of the corresponding mutations is also 
sufficient to rescue the mutant viruses. These results suggested that the interplay of the N 
structural motif with the L-protein may play a role in accessing the nucleotide template without 
disrupting the overall structure of the nucleocapsid.   
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3.2 Introduction 
Negative strand RNA viruses (NSVs) include a number of important human pathogens, 
such as Ebola, avian influenza, and respiratory syncytial virus. Understanding the mechanism of 
their replication assists in the development of new therapies. One unique feature that separates 
NSVs from other viral pathogens is that their genomic RNAs are sequestered in the nucleocapsid 
during viral RNA synthesis. NSVs encode their own viral RNA-dependent RNA polymerase 
(vRdRp). During viral RNA synthesis by vRdRp, the assembled nucleocapsid serves as the 
template, not the released RNA genome (118, 119). The mechanism by which vRdRp gains 
access to the sequestered genomic RNA to copy complementary RNAs is an unsolved question. 
Vesicular stomatitis virus (VSV) is a prototypic NSV. VSV belongs to the Rhabdovirus 
family and its genome encodes five viral proteins, nucleocapsid (N), phosphoprotein (P), matrix 
(M), glycoprotein (G) and the large protein (L).  vRdRp of VSV is composed of the L and P-
proteins, whereas the nucleocapsid, assembled by polymerization of the N-proteins, serves as the 
template. The crystal structure of a nucleocapsid-like particle (NLP) shows that the assembly of 
VSV nucleocapsid requires extensive interactions of a long N-terminal arm and a large loop in 
the C-terminal domain of the N-protein between four neighboring subunits (89, 174). The RNA 
is sequestered between the N-terminal and C-terminal domains that are formed mostly with α-
helices. Some of the bases in the sequestered RNA face the interior of the N-protein such that 
they could not be copied without first being exposed. One possible way is to induce an open N 
conformation as observed in the structure of some RNA-free N subunits (219, 220). However, 
that will also require untangling the interactions between the N subunits, which does not seem 
feasible.  Another possible way is to induce a local conformational change at a proposed access 
gate in the N-protein, which will not disrupt the overall structure of the nucleocapsid. This 
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proposed access gate is one of helices in the N-terminal domain, helix 5, which covers the 
sequestered RNA. If vRdRp can induce a conformational change of helix 5, the sequestered 
RNA would be exposed to serve as the nucleotide template. The structure of the L-protein has 
been solved (117), as well as the nucleocapsid binding domain of the P-protein bound to the 
nucleocapsid (141). The orientation of the P domain bound to the nucleocapsid suggest that 
nucleocapsid bound vRdRp faces the access gate of the sequestered RNA. In this position, 
vRdRp may open the helix-5 access gate to release the sequestered RNA.  
In this report, we tested the requirement of L-N interplay for viral RNA synthesis. 
Mutagenesis studies confirmed that the structural motif consisting of the helix 5 and the 
following loop may play a role in supporting viral RNA synthesis. Since the helix 5-loop motif is 
at one of the most flexible regions in the N-protein, vRdRp could readily induce a conformation 
change in this structural motif to unveil the sequestered RNA when bound to the nucleocapsid. 
The local structural change induced by vRdRp will not disrupt the overall structure of the 
nucleocapsid. 
3.3 Results 
3.3.1 The flexible structural motif in the N-protein 
When the N and P-proteins of VSV were expressed in E. coli, a nucleocapsid-like particle 
(NLP) could be purified (144). The crystal structure of the NLP revealed that the N-protein has 
an extended N-terminal arm and a large C-terminal loop (89). The nucleocapsid is assembled by 
extensive interactions between the N subunits to sequester the viral RNA in the core (174). Once 
the nucleocapsid is assembled, the overall structure is fairly stable except for two regions as 
shown in Figure 3.1. Based on the B-factors, the C-terminal loop and the helix 5/subsequent 
loop (helix 5-loop) are the most flexible regions in the NLP. The structural motif composed of 
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the helix 5-loop forms the access gate to the sequestered RNA. In the NLP, the sequestered RNA 
is inaccessible if the helix 5-loop gate is in place. On the other hand, the flexible C-terminal loop 
is shown to interact with the nucleocapsid-binding domain of the P-protein (141). This 
interaction, however, still maintains the sequestering of the viral RNA. During the viral RNA 
synthesis, vRdRp must gain access to the sequestered RNA in order to use it as the nucleotide 
template. Since the helix 5-loop motif covers the sequestered RNA and is flexible, the 
sequestered RNA may be locally released if a conformational change of the helix 5-loop motif 
could be induced by vRdRp, which could be accomplished without interrupting the nucleocapsid 
assembly. 
3.3.2 The role of the helix 5-loop motif 
As shown in Figure 3.1, several residues are exposed on the surface of the helix 5-loop 
motif. Residues Arg153, Met157, Cys164, Lys165 and Asn168 are located on the helix 5, 
whereas Glu169, Phe171 and Leu174 are located on the loop.  An alanine-scanning mutagenesis 
was carried out to verify the role of each residue in viral RNA synthesis. After each mutation 
was introduced in the plasmid expressing the N-protein, the activity of viral RNA synthesis was 
quantitated in a minigenome assay (221) (Figure 3.2). Mutations of most residues in helix 5 did 
not significantly change the activity, but obvious reduction was observed by the Met157Ala 
mutation. On the other hand, mutation of residues on the loop dramatically reduced the activity 
of viral RNA synthesis. This observation strongly suggests that the loop in this structural motif 
may play an important role in supporting viral RNA synthesis by vRdRp.   
To ensure ubiquitously distributed protein concentrations, the protein expression level of 
N mutants was measured by western blot (Figure 3.2C). Most N mutants showed a similar level 
of protein expression except for L174A that had a 33% expression level compared to the wild 
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type N-protein. For most of the N mutants, the protein expression level was not the main factor 
responsible for reduction of viral RNA synthesis. In case of L174A, reduction in N-protein 
expression may not play a major role in reduction of viral RNA synthesis. 
3.3.3 Nucleocapsid assembly of N mutants 
To examine the effects of N mutations on the assembly of the nucleocapsid, these 
mutations were introduced in our expression system of a nucleocapsid-like particle (NLP) (144). 
The crystal structure of the NLP revealed the molecular interactions in the nucleocapsid (89) and 
NLP recapitulates the assembly of nucleocapsid as found in VSV virion (90). The N mutants 
were co-expressed with the P-protein in E. coli and NLPs were purified as in (144). The elution 
position of the N mutant complexes in the size exclusion chromatography confirmed that the N 
mutants formed the same NLP as the wild type N-protein (Figure 3.3A). Electron micrographs 
of negative stain images of the NLPs clearly showed the ring-like structure of mutant NLPs that 
contain 10 N subunits as the wild type NLP (Figure 3.3B).  
3.3.4 Specific effects of N mutants on viral RNA synthesis 
There are three types of viral RNA synthesized during VSV infection: mRNA during 
transcription, and cRNA/vRNA during replication. To dissect which specific types of viral RNA 
synthesis were affected by the N mutations, each species of the viral RNAs were quantitated by 
RT-qPCR in the minigenome assay (Figure 3.4). The minigenome contains the leader and trailer 
sequences of the full length genome and the luciferase reporter gene. As shown in Figure 3.4, 
the levels of mRNA and cRNA were reduced the most when N mutants were included in the 
minigenome assays. Since vRNA could also be produced by the minigenome plasmid, the level 
of vRNA in this assay would be the mixture of two sources. Based on the changes of vRNA 
levels, the level of mRNA was changed to a large degree compared to the wild type, consistent 
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with the reduction in luciferase activities. For L174A mutant that has a reduced level of protein 
expression, the vRNA level was similar to that when the wt N was included in the minigenome 
assay, suggesting that effects on viral RNA synthesis was not due to the protein level of the N 
mutant. 
3.3.5 Compensatory mutations in other viral proteins 
If the loop residues are involved in supporting viral RNA synthesis by vRdRp, it may be 
expected that compensatory mutations in other viral proteins can restore the activity of viral 
RNA synthesis by vRdRp. To identify the compensatory mutations, each of the mutations in the 
loop was introduced in the N gene of the genome of the parent VSV and mutant viruses were 
rescued by reverse genetics (222). At first, the mutant viruses were passaged five times in BHK-
21 cells at 31 °C at a low MOI of 0.01 to avoid the potential formation of defective interfering 
(DI) particles. In the last round, mutant viruses were harvested 24 h post-infection, and virus 
titers were determined by plaque assays.  Subsequently, mutant viruses passaged at 31 °C were 
used to infect BHK-21 cells at 37 °C with a MOI of 1.0, followed by three more passages using a 
MOI of 0.01 and titering by plaque assays. Serial passages were continued until the virus titers 
reached 1×107 PFU/mL (similar as wt VSV). The viruses from the last round were plaque 
purified in HeLa cells and the genome was sequenced for each mutant virus (Table 3.1). 
Compensatory mutations were identified in the L-protein of all three mutant viruses, confirming 
the critical role of the helix-loop motif in the interplay between the N and L-protein to support 
viral RNA synthesis. In addition, a compensatory mutation was also found in the P-protein in 
mutant Niii (Leu174Ala). This is also consistent with the role the helix-loop motif in supporting 
vRdRp activities because the interactions of P with N contribute to the activity of viral RNA 
synthesis (223, 224). More interestingly, mutations were also identified in the N-protein (Table 
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3.1). This suggests that optimal correlations between L and N are required for efficient viral 
growth. No mutations were found in M and G proteins. 
We noticed that the mutant viruses passaged at 31 °C did not grow well when they were 
first transferred to 37 °C. This indicates that the initial compensatory mutations meet the 
minimum requirements to restore the viral RNA synthesis. Further compensatory mutations are 
required to fully restore the activity of vRdRp or effective virus assembly at 37 °C.  
3.3.6 Verification of the compensatory mutations 
Compensatory mutations identified in the rescued mutant viruses were introduced in the 
plasmids expressing N, P and L-proteins, respectively, and the minigenome assays were 
repeated. As shown in Figure 3.5, the compensatory mutation in the L-protein alone is not 
sufficient to restore the activity of viral RNA synthesis with the Ala mutations of Glu169 and 
Leu174 introduced in the N-protein. In case of Phe171, the mutation to Ala did not result in a 
large reduction of viral RNA synthesis and the single compensatory mutation of Arg998Gln in 
the L-protein is sufficient to restore the activity. Additional mutation of Leu110Val in the N-
protein did not further enhance the activity of viral RNA synthesis, implying this mutation may 
be related only to the assembly of the virus. On the other hand, all compensatory mutations are 
required for Glu169 and Leu174 mutations in order to fully restore the activity. The minigenome 
assays confirmed that the Leu174Val mutation is required for full restoration of the polymerase 
activity.  
3.3.7 Confirmation of compensatory mutations required for virus replication 
To verify that the identified compensatory mutations are sufficient to construct a viable 
mutant virus, the mutations from the three mutant viruses were introduced in the genome of the 
parent VSV and virus rescue was carried out subsequently. Mutant viruses corresponding to all 
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N mutations were successfully rescued and grew to similar titers as the parent VSV and wt VSV 
(Figure 3.6). This result confirms that mutations identified in these mutant viruses can produce 
viable viruses when they are introduced in the parent virus. 
3.4 Discussion 
The mechanism of viral RNA synthesis by NSV vRdRp is unique because the template is 
the nucleocapsid, not the free RNA genome. Since the genomic RNA is sequestered in the 
nucleocapsid, vRdRp must induce structural changes in the N-protein in order to gain access to 
the sequestered RNA. Another important requirement is that the integrity of the nucleocapsid 
must be retained after the viral RNA synthesis is terminated. The size of vRdRp (117) suggests 
that the sequestered RNA may be locally released by vRdRp, without disrupting the overall 
structure of the nucleocapsid.  
The atomic structure of the nucleocapsid and the N-protein has been determined for a 
number of NSVs, and in the form of NLP, empty NLP or the N subunit (85-87, 89, 147, 174, 
203-205, 219, 220, 225-237). As shown by the vast amount of structural data, the common 
scheme of nucleocapsid assembly of NSVs involves extensive cross-subunit interactions by 
termini or loops extended from the core of the N-protein (112). These extensive interactions 
make the overall structure of the nucleocapsid very stable. This raises the question how vRdRp 
may gain access to the sequestered RNA. Based on an open conformation found in the RNA-free 
N subunit (219, 220), one possible mechanism is to induce the open conformation of the N-
protein by vRdRp. However, this mechanism would require a large conformational change (up to 
30 ° rotation) of the domains in the N-protein, and disruption of the cross-subunit interactions by 
the extended polypeptides. This not only requires broad interactions between vRdRP and the 
nucleocapsid, but also may result in disassembly of the nucleocapsid. The open conformation of 
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the N-protein is stabilized by the chaperone P-protein to serve as the precursor for nucleocapsid 
assembly. The assembly of the nucleocapsid may not be a reversible process after it has been 
completed and the P-protein been released from the assembled nucleocapsid.  
In this study, we focused on a structural motif of the helix 5-loop in the N-protein of VSV 
that constitutes the access gate to the sequestered RNA. This structural motif is one of the two 
flexible regions in the nucleocapsid, suggesting its conformational changes are more easily 
induced by interactions with vRdRp. Structural changes of the helix 5-loop are expected to be 
local and would not disrupt the nucleocapsid assembly. Previous studies showed that residues on 
helix 5 directly interact with the sequestered genomic RNA and are essential for RNA 
encapsidation and viral RNA synthesis (89, 177). The structure of the nucleocapsid binding 
domain of the P-protein bound in the NLP indicated that vRdRp would face the helix 5-loop 
motif when it binds the nucleocapsid (141), implying a direct contact between them. Our 
mutagenesis studies proved that residues Met157, Glu169, Phe171 and Leu174 in the helix 5-
loop motif are essential for the activity of viral RNA synthesis. The N mutations do not interrupt 
the assembly of the nucleocapsid and appear to mainly affect the synthesis of mRNA and cRNA. 
Compensatory mutations in vRdRp (L and P-proteins), as well as those in the N-protein, can 
restore the activity of viral RNA synthesis. These mutations are also sufficient to generate a 
viable mutant virus when introduced in the wt viral genome. Since the initial mutations we 
introduced in the N-protein were alanines, which eliminates the potential interactions of the wt N 
residues with other proteins, residues resulted from compensatory mutations may not directly re-
establish interactions with the mutated Ala, but rather interactions with the helix 5-loop motif. 
This is also consistent with the observation that additional mutations in the N-protein are 
required to fully restore the activity of vRdRp.  Nevertheless, our study confirmed that potential 
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interactions of the helix 5-loop motif with vRdRp may be required for viral RNA synthesis in 
VSV. A similar flexible structural motif is also found in the N-protein of paramyxoviruses 
(Nipha virus, parainfluenza virus 5 and mumps virus), suggesting a common mechanism for 
accessing sequestered RNA in NSV nucleocapsid (219, 233, 238). 
3.5 Methods 
3.5.1 Cell culture, viruses  
BSR-T7 (a gift from Dr. Biao He, University of Georgia) and BHK-21 cells were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM) containing 5% fetal bovine serum 
(FBS) with 100 units of penicillin, 20 units of streptomycin (221). BSR-T7 cells were 
additionally supplemented with Geneticin G418 (1mg/ml) on every second passage. HeLa cells 
were maintained in DMEM containing 10% FBS 100 units of penicillin, 20 units of streptomycin 
(239). Recombinant vaccinia virus vTF7-3 were prepared in CV-1 cells cultured in Eagle’s 
Minimum Essential Medium (EMEM) supplemented with 10% FBS.  
3.5.2 Plasmid mutagenesis  
The original plasmids pLuc, pN, pP and pL were kindly provided by Dr. Asit K. Pattnaik 
at University of Nebraska-Lincoln. pLuc was constructed in pGEM-3 vector by inserting a leader 
sequence, the luciferase gene and a trailer sequence (194). pN, pP and pL were used to express 
N, P and L-proteins of VSV. All site- directed mutations in N, P and L genes were constructed 
using Q5 Site-Directed Mutagenesis Kit (New England Biolabs) following the manufacturer’s 
instructions. The same method was also used to introduce site-directed mutations in the full 
length VSV genome. 
The wt full-length VSV genome plasmid is a gift from Dr. Gail Wertz at the University 
of Alabama at Birmingham. The full-length VSV (Indiana serotype) genome was modified by 
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inserting the coding sequence of a mCherry protein fused at the N-terminus of the P gene (mcP 
VSV), using the overlap PCR method (Table 3.2).  
3.5.3 VSV minigenome assay 
BSR-T7 cells seeded to approximately 95% confluency in 12-well plates were infected 
with vTF7-3 at a MOI of 1-5 for 1 h at 37 °C. Cells were washed twice with Opti-MEM serum-
free medium (Invitrogen) and transfected with 2µg pLuc, 1.5 µg of pN, 1 µg pP and 0.5 µg of 
pL, by using Lipofectamine 2000 (Invitrogen) (194). The cells were incubated for 6 h at 37 °C, 
and then fresh DMEM with 5% FBS was exchanged. At 24 hpt, cell lysates were assayed for the 
luciferase activity.  
3.5.4 Western blot 
Western blots were performed as described previously (240). Lysates were prepared from 
BSR-T7 cells transfected with N-WT, N-E169A, N-F171A and N-L174A. Samples were run on 
8.5% acrylamide SDS-PAGE gels and Western blot was probed with specific antibodies for anti-
VSV N and developed using PierceTM ECL Western Blotting Substrate (ThermoFischer 
Scientific). 
3.5.5 N-protein expressions and purifications 
All of cDNA mutations were cloned into the expression vector previously shown (117) 
using the HiFi assembly kit with the forward primer (5’-
CTTAAGAAGGAGATATACCATGGCTTCTGTTACAGTCAAG-3’) and the reverse primer 
(5’-GATGGCCCATGGTATATCTCCTTCATTGTCAAATTCTGAC-3’) according to the 
manufacturer’s protocol. Positive clones were identified by sequencing and transformed into E. 
coli strain BL21 (DE3). The N-rings were expressed and purified as previously described (144). 
After purification, size exclusion was carried out with a HiLoad 16/100 Superdex 200 prep grade 
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column equilibrated with 50 mM Tris pH 7.5 and 300 mM NaCl. The second peak, 
corresponding to the pure NLPS, was analyzed by SDS-page for purity, and then utilized for 
further TEM experiments. 
3.5.6 Transmission Electron Microscopy  
Images were taken at 30K magnification on a JEOL JEM-1400 (120 kV) TEM using a 2k 
x 2k, 14µm Ultrascan1000 (Gatan). Samples grids (25 μg/mL concentration of protein) were 
prepared by adding 2μL onto a carbon coated, 400 mesh copper grid. After 1 minute, the sample 
was blotted with Whatman 4 filter paper. A 2µL buffer wash/blot step was added before staining 
with 4% uranyl acetate for 30 seconds and blotting away excess. All particle picking and 2D 
class averages were done in EMAN2 and selected class averages and particles are shown in 
Figure 3.3  (241).  
3.5.7 Virus rescue 
mcP VSV was used as the parent VSV to construct the mutant virus genome, following 
the procedures described previously (222, 242-244). Briefly, confluent 60-mm dishes of BSR-T7 
cells were infected with vTF7-3 at a MOI of 10. After 45 min, the cells were co-transfected with 
a plasmid encoding the full length VSV genome containing various mutations in the 
corresponding viral genes (4 µg), and pN (6 µg), pP (4 µg) and pL (2 µg) proteins in 20 µL of 
Lipofectamine 2000. After 48-72 h, the culture medium was collected, filtered through a 0.22 
µm-pore-size syringe filter twice to remove vTF7-3 vaccinia virus. Viral titers were determined 
by a plaque assay as described previously (245).  
3.5.8 Plaque purification of rescued viruses.  
Briefly, monolayers of Hela cells were grown in 12-wells tissue culture plates. Cells were 
infected with inoculums of the mutant virus 10-fold serially diluted in DMEM without serum. 
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After 1 h incubation at 37 °C in 5% CO2, the infection medium was then aspirated and washed 
three times with phosphate-buffered saline (PBS), and overlaid with 1 mL of 0.8% (wt/vol) 
agarose in DMEM. After 24 h incubation, four plaques were picked from at least 2 different 
wells. The agarose plugs were individually transferred to 60mm plates of BHK-21 cells. Virus 
growth was monitored by observing mCherry using fluorescence microscopy and virus titers 
were determined by plaque assays. 
3.5.9 RNA extraction and reverse transcription-PCR (RT-PCR)  
Viral RNAs were extracted from infected cell cultures by using the RNeasy Mini Kit 
(QIAGEN) following the manufacturer’s instructions, and the total RNA was used in reverse 
transcription to generate cDNA by using random Nonamers (Sigma) as described previously 
(223, 246). Briefly, the 20 µL reaction mixtures contained 10 µL of RNA, 4 µL 5×first-strand 
buffer, 1 µL random nonamers primers (Sigma), 1 µL 10mM dNTP Mix, 2 µL 0.1 M DTT, 1 µL 
RNaseOUT inhibitor, and 1 µL of SuperScript II Reverse Transcriptase (Invitrogen). The 
samples were incubated at 42°C for 1 h, and the reaction was inactivated by heating at 70 °C for 
15 min. The PCR reactions were performed by using Phusion High-Fidelity DNA Polymerase 
(Thermo Fisher). 
3.5.10 Real-time qPCR 
Total RNA was extracted, as described above, from BSR-T7 cells from either the mock, 
treated, or transfected with the different Luciferase minigenomes . The reverse transcriptions 
were performed using the same protocol as above, but by using the specific primers for  (mRNA, 
5’-CCAGATCGTTCGAGTCGTTTTTTTTTTTTTTTTTTTACACGGCGATCTTGCC-3’), 
cRNA, 5’-GCTAGCTTGAGCTAGGCATCCGCCGATATCTGTTAG-3’), vRNA, 5’-
GGCCGTCATGGTGGCGAATACGAAGACAAACAAACC-3’), and (β-actin, 
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5’AGCACTGTGTTGGCGTACAG-3’).  Real-time PCR was performed using the mRNA 
forward primer (5’-CCAGATCGTTCGAGTCGT-3’), and reverse primer 
(5’CGCGGTGGTGTTGTGTTC-3’), the cRNA forward primer (5’-
GCTAGCTTCAGCTAGGCATC-3’) and reverse primer (5’-AAACAGAAAACCGACACCTG-
3’), the vRNA forward primer (5’-AGCAGGTTTGTTGTACGC-3’) and reverse primer 
(5’GGCCGTCATGGTGGCGAAT-3’), and the β-actin forward primer (5’-
AGAGCTACGAGCTGCCTGAC-3’) and reverse primer (5’-AGCACTGTGTTGGCGTAGAG-
3’) on an QuantStudio 3 Real-Time PCR System utilizing the PowerUp Sybr Green Master Mix 
and the manufacturer’s protocol (Thermo Fisher Scientific). All data was analyzed using the 2-
ΔΔCT method as previously described and the mock, the template free, the no RT-PCR, and the 
template only controls did not yield a CT value (data not included) after 40 cycles indicating 
specific amplification of the selected genes (247).  
3.5.11 Sequence analysis of viral genomes 
The primers shown in Table 3.3 were used to amplify the full-length VSV genomes. 
Each fragment was cloned into pCRTM2.1 vector containing LacZ gene (Invitrogen). Automated 
sequence analysis was carried out by DNAStar 7.0 software. Determination of growth kinetics. 
Multi-step growth curves were generated using a protocol similar to that previously described 
(248). Briefly, BHK-21 cells seeded to approximately 95% confluency in 12-well plates were 
infected with each of the mutant viruses at a MOI of 0.01. After 1 h of adsorption at 37 °C in 5% 
CO2 with periodic rocking, the inoculum was removed. The cells were washed 3 times with PBS 
to remove unbound virus and then 1 mL of DMEM was added. At the indicated time points (6 h, 
12h, 18 h, 24 h, 30 h, and 36 h), the supernatant of each well was collected and stored at -80 °C 
for determination of the virus titer by a plaque assay in a later time. 
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Flexibility of the N-protein. (A) A B-factor putty drawing of the N-protein structure in the 
nucleocapsid-like particle. The regions colored red also have a large diameter, which 
corresponds to higher B-factors and are associated with higher structural flexibility. The 
sequestered RNA was shown as a stick model. (B) A close-up look at the helix 5-loop motif. The 
red color of the models also corresponds to high B-factors. Selected residues are shown as stick 
models and labeled. The drawings were prepared with PyMol. 
  
 
Figure 3.1 Flexibility of the N-protein 
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Role of each exposed residue. (A) Illustration of the minigenome construct and the list of alanine 
mutations for the surface exposed residues in the helix 5-loop motif. Cys164 was also mutated to 
an alanine (green) as a control. (B) Luciferase activities in the minigenome assays. Mutations of 
the N-protein in pN and controls were labeled. (C) Protein expression levels of N mutants in the 
minigenome assays as determined by western blot. 
 
 
 
 
 
 
Figure 3.2 Role of each exposed residue. 
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Mutations do not disrupt the NLP Structure. (A) Elution profile of NLPs from a S200 size 
exclusion column. The light blue line corresponds to wt NLP, the red line corresponds to E169A, 
the dark green line corresponds to F171A, and the light green line corresponds to L174A. (B) 
TEM images, class averages, and selected particles of the E169A, F171A, and L174A. Class 
averages were prepared with EMAN2 and particles were selected to show that the mutants still 
assemble in the same way as the wt rings (10 subunits in each assembly).  
 
 
 
 
 
Figure 3.3 Mutations do not disrupt the NLP Structure 
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RT-qPCR quantification of mRNA, cRNA, and vRNA from the minigenome assay. Reduction in 
viral RNA levels of the E169A, F171A, and L174A mutants compared to the wt N, respectively, 
was calculated using 2-ΔΔCT values. The Log2 of 2-ΔΔCT is plotted in the vertical axis to show the 
relative reduction of RNA, and the shade for each viral RNA species is shown. 
 
 
 
 
 
 
 
 
Figure 3.4 RT-qPCR quantification of mRNA, cRNA, and vRNA from the minigenome assay.  
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Table 3.1 Mutations identified in rescued viruses passaged at 37℃. 
Virus Passage N gene P gene L gene 
Ni (E169A)     14 M166I   I753M 
    R179H     
Nii (F171A)     26 L110V   R998Q 
Niii (L174A)     18 L174V S264Y R728K 
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Verification of compensatory mutations. Luciferase activities measured in the minigenome 
assays. The horizontal axis is labeled as the following: controls, P169a (pN-E169A, pP, and pL), 
P169b (pN-E169A, pP, pL-I753M), P169c (pN-M166I/E169A/R179H, pP, pL-I753M), P171a 
(pN-F171A, pP, pL), P171b (pN-F171A, pP, pL-R998Q), P171c (pN-L110V/F171A, pP, pL-
R998A), P174a (pN-L174A, pP, pL), P174b (pN-L174A, pP, pL-R728K), P174c (pN-L174V, pP-
S264Y, pL-R728K) and P174d (pN-L174A, pP-S264Y, pL-R728K). Mutations introduced in the 
plasmids that express the corresponding proteins or the wt plasmids are indicated in 
parentheses.  
 
 
 
Figure 3.5 Verification of compensatory mutations. 
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Growth curves of mutant viruses. Compensatory mutations identified in Ni, Nii and Niii were 
introduced in the genome of the parent VSV (mcP VSV) and the mutant viruses were rescued 
(mcP VSV-Ni, mcP VSV-Nii and mcP VSV-Niii, Table 3.1). Confluent BHK-21 cells were 
infected by each marked virus with a MOI of 0.01. Samples were collected from each infection at 
the given time points and the virus titers were determined by plaque assays. 
 
Figure 3.6 Growth curves of mutant viruses.  
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Table 3.2 Primers used for introducing the mCherry gene. 
 
 
 
 
 
 
Primer Nucleotide sequence (5'—3') 
N(+)-F     CAGCCTGATGACATTGAGTATACATCTCTTACTACAGCAGG 
N-mC(-)-R     TCCTCGCCCTTGCTCACCATGGTGGCGGCGATATCTGTTAGTTTTTTT 
P(+)-F     ATGGACGAGCTGTACAAGggaggaaacagcggaggaATGGATAATCTCACAAAAGTTCG 
P-M(-)-R     GCCTATTAAGTCATTATGCCAATTTAAATCTGAGCTTGACGGGC 
mC(+)-F     TATGAAAAAAACTAACAGATATCGCCGCCACCATGGTGAGCAAGGGCGAGG 
mC-P(-)-R     ACTTTTGTGAGATTATCCATtcctccgctgtttcctccCTTGTACAGCTCGTCCAT 
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Table 3.3 Primers used for amplification of the full-length genome of VSV in sequencing. 
 
 
 
 
 
 
 
 
 
 
 
       Primer               Nucleotide sequence (5'—3') 
   AmpVSV1-F           ACGAAGACAAACAAACC 
   AmpVSV1-R            TCTGAAGTGCTCTGGTAC 
   AmpVSV2-F            TTCTAATCTAAAGGCCAC 
   AmpVSV2-R           CTTCAAGTTGCATATCGG 
   AmpVSV3-F            TAGGGAGGATGCAAACGG 
   AmpVSV3-R            TTGTCGGATAGGAGGTTG 
   AmpVSV4-F            CGGATTAATGAGAGCAAG 
   AmpVSV4-R            ACGAAGACCACAAAACCAG 
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4 CONSTRAINTS OF VIRAL RNA SYNTHESIS ON CODON USAGE OF 
NEGATIVE STRAND RNA VIRUS 
At the time of submission under review at Journal of Virology, 11/18/2018 
4.1 Abstract 
Negative Strand RNA viruses (NSV) include some of the most pathogenic human viruses 
known. NSVs completely rely on the host cell for protein translation, but their codon usage bias 
is often different than that of the host.  This discrepancy may have originated from the unique 
mechanism of NSV viral RNA synthesis in that the genomic RNA sequestered in the 
nucleocapsid serves as the template. The stability of the genomic RNA in the nucleocapsid 
appears to regulate its accessibility to the viral RNA polymerase, thus placing constraints on 
codon usage to balance viral RNA synthesis. By in situ analyses of vesicular stomatitis virus 
RNA synthesis, specific activities of viral RNA synthesis were correlated with the genomic RNA 
sequence. It was found that the purine/pyrimidine content modulates the overall stability of the 
polymerase complex, resulting in altering the activity of viral RNA synthesis. The codon usage is 
therefore constrained by the obligation of the NSV genome to viral RNA synthesis. 
4.2 Introduction 
The Negative strand RNA virus (NSV) family includes some of the most well-known 
human pathogens such as Ebola virus, influenza virus, and respiratory syncytial virus (77, 178-
180). The virally encoded RNA-dependent RNA-polymerase (vRdRp) of NSV must recognize 
the nucleocapsid and unpack the sequestered genomic RNA from the nucleocapsid to use it as 
the template for viral RNA synthesis (118, 119). On the other hand, translation of viral proteins 
completely relies on the translation machinery of the host cell. This host reliance should direct 
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the evolution of the viral codon usage bias (CUB) towards that of the host. This is certainly an 
effective way to optimize virus growth if translation is the major barrier for the virus, as 
observed in positive strand RNA viruses (97).  
However, there is no such coevolutionary virus-host relationship in the genome of NSVs.   
The genome of NSVs maintains a constant CUB, in spite of a high mutation rate by vRdRp (96). 
The calculated mutation rate for Paramyxoviridae is high enough to completely randomize the 
viral sequence 6 times per year, while the observed mutation rate is only about 6 nucleotide 
changes per year (96, 249-251). Furthermore, it has also been noted that the viral CUB can be 
significantly different from the host CUB (96). While this is often attributed to the suppression of 
CpG codons for evading the host immune system (252), the correlation is not ubiquitously 
distributed throughout all NSVs. Other requirements for virus growth may place constraints on 
evolution of NSVs. One factor could be the nucleotide content that is related to interactions of 
the genome with other proteins. Vesicular stomatitis virus (VSV) is a prototypic NSV that 
encodes five viral genes: nucleocapsid (N), phosphoprotein (P), matrix protein (M), glycoprotein 
(G) and large protein (L). A study showed that by altering the Codon Pair Bias score in a portion 
of the L-protein (polymerase) gene, which changes CUB, the virulence of VSV was attenuated in 
mice without changing the efficiency of viral protein translation (253).  
Since NSV vRdRp needs to open the nucleocapsid to access the sequestered genomic RNA 
for transcription/replication, we propose that the stability of the genomic RNA in the 
nucleocapsid plays a regulatory role in the ability of the polymerase to successfully carry out 
viral RNA synthesis. As shown in Figure 4.1A, the nucleocapsid is formed through intricate 
cross-molecular interactions between adjacent subunits, and the accessibility of the genomic 
RNA could vary with the local sequence (89, 174). During viral RNA synthesis, one “stable” 
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sequence could cause the nucleocapsid to tighten and reduce the processivity of vRdRp, whereas 
a different “unstable” sequence could cause the nucleocapsid to loosen and increase the 
processivity of vRdRp or the rate of vRdRp dissociation from the nucleocapsid (Figure 4.1B). 
To verify this mechanism, in situ activities of VSV vRdRp were correlated with altered codon 
usage using minigenome assays. The results show that the balance between purines and 
pyrimidines in the genome sequence plays an essential role in regulating the polymerase activity. 
The requirements for transcriptional/replicational control constrain codon usage of NSVs, which 
explains why NSVs maintain their independent genomic stability despite reliance on the host 
machinery for viral protein translation. 
4.3 Results 
4.3.1 Effects of Changing the Codon Usage Bias on Transcription/Replication 
 In order to investigate the effect that CUB has on transcription/replication, CUB of the 
VSV genome was compared to that of human and the sand-fly, two of VSV hosts (Table 4.4). 
Furthermore, a similar analysis was extended to the genomes of Ebola virus and Influenza virus. 
Compared to CUB in human, codons highlighted in green are more frequently used in VSV and 
codons in red are less frequently used. It is obvious that CUB of VSV does not match that of 
human or sand-fly. A similar CUB pattern was also observed in Ebola virus and Influenza virus, 
indicating that this phenomenon could be ubiquitous throughout the NSV family.  
A minigenome system was designed to quantitate in situ activities of vRdRp on VSV 
nucleocapsid (Figure 4.2A). The N gene was selected to represent the VSV genome. There are 
long stretches of green and short interspersed patches of red throughout the N gene (Figure 
4.2D). This minigenome system is useful for comparable measurements of the vRdRp activities 
when the nucleotide content of the genome is altered. For comparisons with the wt minigenome 
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(247), one synthetic genome was recoded such that codons with low usage frequency (in red) 
were changed to those with high usage frequency (named as the high usage genome) and another 
synthetic genome was recoded such that codons with high usage frequency (in green) were 
changed to those with low usage frequency (named as the low usage genome). During the NSV 
life cycle, three species of RNA are produced: mRNA (during transcription), cRNA (during 
replication), and vRNA (during replication). In the minigenome assays, each RNA species was 
quantitated by RT-qPCR. In the top panel of Figure 4.2B, the full-length RNA levels from 
genomes with different CUBs were compared. For mRNA, ~744 fold reduction was observed for 
the high usage genome relative to the wt genome, and ~750 fold reduction, for the low usage 
genome. For cRNA, reduction of ~39 fold and ~55 fold were observed, respectively, and for 
vRNA, reduction of ~5.5 fold and ~1.8 fold were observed, respectively, for the high and low 
usage genomes. These observations clearly indicate that the activity of vRdRp is severely 
compromised during transcription and replication by just switching CUBs.  
To further dissect which specific step in viral RNA synthesis is more affected by a 
change in CUB, eight chimeric minigenomes between the wt genome and either high or low 
usage genome were constructed (Figure 4.2C) based on the golden ratio. Among these chimeras, 
N1, N2, and N3 show statistically significant reduction in mRNA levels, while N4 shows a non-
statistically significant increase. In the chimeric genome, N1, N2, and N3 all have either an 
altered CUB in the transcription (or replication) initiation or termination portion of the sequence, 
whereas N4 has the wt CUB in both. This would indicate that for transcription of mRNA, the 
CUB is more stringent for initiation and termination by vRdRp. This is consistent with the 
requirements for transcription by VSV vRdRp because viral transcription must be initiated and 
terminated at the correct position in order to balance the levels of all five mRNAs encoded in the 
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polycistronic genome. For cRNA and vRNA, on the other hand, it seems that elongation is the 
most affected activity of vRdRp since the initiation and termination of replication are more 
dependent on the 3’ and 5’ noncoding sequences (named the leader and trailer sequences, 
respectively), neither of which was changed in the chimeric genome. The largest reduction in 
genomic RNA levels was observed when the genomes with a large portion of altered CUB (N2 
and N4) were used as the template. After initiation of replication, the processivity of vRdRp is 
dependent on CUB when it copies the entire genome. 
It is possible that reduction in levels of full length RNAs was due to premature 
termination.  Another set of primers was designed to quantify RNAs from any possible early 
termination during transcription and replication. The RNAs quantitated by these primers 
correspond to total RNAs of the shortened RNAs, in addition to the full length RNAs. As shown 
in Figure 4.2B, levels of the total mRNA transcripts were increased by ~19 fold and ~35 fold, 
respectively, for the high and low usage genomes. It is also interesting that the total mRNA was 
twice of the full length mRNA when the wt genome was used, indicating the common presence 
of early termination in transcription. An increase in shortened mRNA transcripts was observed 
across all of the chimeric minigenomes. This effect is exacerbated across the high usage 
chimeras, especially for N2, N3, and N4. On the other hand, an increase in shortened cRNA and 
vRNA was observed for the low usage chimeras, but less increase in shortened mRNA 
transcripts compared to those of the high usage chimeras.  
4.3.2 The role of the Purine and Pyrimidine Ratio in Nucleocapsid Stability 
 In the nucleocapsid, the bases of the sequestered RNA stack in a consistent manner in 
each subunit (Figure 4.1C)(14). The first four bases stack with each other, the 5th base stacks 
with bases of 7 and 8, and the 6th base flips out of the stacked bases. The strength of π-stacking 
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interactions is in the order of purine-purine>purine-pyrimidine>pyrimidine-pyrimidine (254). 
We therefore hypothesized that sequences more rich in stacked purines would yield a more stable 
nucleocapsid, which is consistent with the structures of nucleocapsid-like particles (NLPs) that 
encapsidate poly(rA) (173, 255).  
The sequence analysis technique Kappa Index of Coincidence (Kappa IC) was often used 
to identify different classes of promoters in eukaryotes (256). Kappa IC measures the probability 
of finding a repeating pattern in a nucleotide sequence. In this case, the purine content (A+G%) 
vs Kappa IC was plotted for the wt, high, and low usage genomes. Since Kappa IC is sensitive to 
simple or short tandem repeats, and window sizes, the calculation was carried out using various 
window sizes (Figure 4.3A) (256). Analysis of the template strand for mRNA synthesis revealed 
that there is a slightly lower degree of purine content for the high usage genome compared to that 
of the wt genome when the window size was 9 or 18 nucleotides. The more significant indication 
was that the lower (A+G%) in the high usage genome was associated with a higher KIC, shown 
by a large tail in the upper left portion of the graph. High KIC suggests that pyrimidines were 
more clustered in the high usage genome, leading to more pyrimidine stacking (257). As the 
window size increases, the left portion of the graph was more densely packed, further indicating 
the presence of larger stretches of pyrimidines. At the same time, the center of mass in each plot 
with smaller window sizes is consistently associated with higher Kappa IC scores for the high 
usage genome, consistent with a higher pyrimidine clustering at the local sequence level. When 
larger window sizes were used, the center of mass shifts slightly more to the right, almost 
overlapping with that of the wt genome (on the X-axis), indicating that the clustered pyrimidine 
content of the wt and high usage genomes matches more closely at a global level. This confirms 
that the local purine/pyrimidine clustering may play an important role in regulating vRdRp 
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activities in transcription. For the low usage genome, on the other hand, there is a significant tail 
to the right of the graph and right-shift of the center of mass throughout all window sizes. This is 
indicative of a higher purine content and clustering, while the overall clustering of purines and 
pyrimidines matches that of the wt genome.  
To verify that the stability of the nucleocapsid is related to the purine/pyrimidine content, 
Thermal Shift Assays (TSA) were carried out with recombinantly purified NLPs (144, 173, 258). 
A selected piece of RNA could be reconstituted in the NLP by removing the original RNA with 
RNase A and subsequent incubation with the selected RNA (173). Melting curves of NLPs with 
poly(rA) and poly(rU) sequences were determined (Figure 4). The results showed that 
incorporation of poly(rA) in the NLP increased the stability by 2.33 ᵒC compared to the 
recombinantly purified NLP with random RNA sequence (173), and 2.96 ᵒC compared to the 
NLP with poly(rU). Furthermore, incorporation of poly(rA) in the NLP delayed the thermo-
release of RNA by 7.86 ᵒC compared to the recombinantly purified NLP with random RNA 
sequence, and 8.81 ᵒC compared to the NLP with poly(rU) (258). Both of these experiments 
depict a large stabilization of the NLP by poly(rA). This is consistent with a previous study in 
which a polyamide (UMSL1011) that stabilizes the RNA in NLP delayed RNA thermo-release 
by 2.04 ᵒC (258). These experimental results confirmed that the nucleocapsid stability is 
dependent on the purine content of sequestered RNA, which may change the accessibility of the 
genomic RNA in the nucleocapsid to vRdRp to modulate its transcription/replication activities. 
4.4 Discussion 
The high mutation rate of vRdRp has been related to virus evolvability and replication 
(259). In positive strand RNA viruses, the faster genome replication and optimal codon usage 
select viruses with good fitness (260-262). Since RNA viruses rely on the host cell for protein 
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translation, CUB of positive strand RNA viruses is similar to that of the host cell since its 
genomic RNA is also used as the messenger RNA for protein translation (263, 264). In NSVs, 
however, their CUB does not match that of the host cell despite their reliance on host protein 
translation. This phenomenon has previously been attributed to limiting CpG to evade the host’s 
immune system and to a concept of codon constellation (96, 252, 264-266). More importantly, 
analyses of codon usages revealed that CUB of NSVs was not resulted from transitional selection 
(267-269). To identify other factors of CUB selection in NSVs, viral proteins that have close 
interactions with the coding regions of the viral genome are considered. One of the unique 
mechanisms that control viral genome replication of NSVs is that the template used by vRdRp in 
viral RNA synthesis is the nucleocapsid. The entire viral RNA genome is completely sequestered 
by the N-protein (85, 89) and its access to vRdRp may regulate viral RNA synthesis in NSVs 
(117, 173).We hypothesize that the access to the genomic RNA sequestered in the nucleocapsid 
constrains codon usage by NSVs, which is a determinantal factor in CUB selection during NSV 
evolution.  
These constraints were examined in this study by evaluating in situ activities of VSV 
vRdRp using a minigenome assay. Our data showed that vRdRp became highly dysregulated 
with large decreases in transcription and replication when the codon usage in the VSV 
minigenome was deoptimized (Figure 4.2B). Changes in viral RNA synthesis were not related to 
protein translation since all viral proteins were produced by other vectors. This clearly confirmed 
that the nucleotide sequence of the viral genome in the nucleocapsid plays an essential role in 
regulating viral RNA synthesis by vRdRp. In an effort to identify which steps are more affected 
by changes of codon usage, eight chimeric minigenomes were also created. The results showed 
that the regions corresponding to initiation and termination of gene transcription had more 
100 
dramatic detrimental effects on vRdRp activities when CUB was deoptimized (Figure 4.2B and 
4.2C). In the context of the virus genome, this is consistent with that vRdRp is required to 
accurately initiate and terminate mRNA transcription in order to balance the transcript products 
from the polycistronic genome (270). For replication, elongation of cRNA and vRNA was most 
limited by CUB changes because the ends of the genome, which regulate the initiation and 
termination of genome replication by vRdRp, were not changed. 
 The consequence of CUB changes was analyzed for nucleotide contents and 
clustering.  Since the crystal structures of VSV NLP suggest that purines have more stable base 
stacking (89, 173), an increase or decrease in (A+G%) and their clustering may alter the access 
of the sequestered genomic RNA to vRdRp. (A+G%) was calculated and compared with KIC for 
high and low usage genomes (Figure 4.3A). Since KIC is a measure of randomness, a deviation 
from the wt sequence could potentially deregulate viral RNA synthesis. The results showed that   
pyrimidine clustering was increased in the high usage genome and purine clustering was 
increased in the low usage genome. An abnormal stability of the nucleocapsid could not maintain 
the precise activities of vRdRp. To further corroborate the correlation of (A+G%) and their 
clustering with levels of viral RNA synthesis, thermal shift assays were used to measure the 
stability of the nucleocapsid when different RNA sequences were encapsidated. The results 
showed that NLPs were stabilized by the presence of purine sequences and destabilized by the 
presence of pyrimidine sequences in comparison with the recombinantly prepared NLP that 
encapsidates random RNAs. These data directly support that the nucleotide content and base 
clustering of the NSV genome, as a consequence of CUB selection, regulates the vRdRp 
accessibility of the genomic RNA sequestered in the nucleocapsid. The regional accessibility of 
the genomic RNA may be increased by reducing A+G content or clustering, but early 
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termination could also be increased. Evolution of NSVs results in their own CUB that balances 
mRNA transcripts and efficient genome replication. 
 Insights on the evolutionary principles of CUB in NSVs have great implications 
in managing outbreaks of highly pathogenic viruses, such as Ebola virus, influenza virus and 
rabies virus. Analyses of codon usage in these viruses (252, 269, 271, 272) found that these 
NSVs constantly mutate in different hosts, but their CUB was not coincident with that of the 
host. Our conclusion that optimal viral RNA synthesis regulated by the nucleocapsid is an 
additional determinant factor in CUB selection of NSVs will lead to an improved algorithm for 
mapping the evolution trajectory of these pathogens. That will greatly help in design of 
detection, vaccines and antiviral treatment for emerging NSVs. 
4.5 Methods 
4.5.1 Minigenome Plasmid 
The pN, pP, and pL plasmids were provided by Dr. Asit K. Pattnaik at the University of 
Nebraska-Lincoln. The template for the minigenome was constructed as previously shown (194). 
To insert the N gene into the minigenome template, the Luc gene was removed from the 
minigenome using BamHI. The N gene was amplified from pN using primers as shown in Table 
4.1, with BamHI cleavage sites on each side. This fragment was then cloned into the 
minigenome vector. In order to create a PCR-tag for the mRNA transcribed from the 
minigenome, mutations corresponding to primers shown in Table 4.1 were introduced using the 
Q5 Site-Directed Mutagenesis Kit (New England Biolabs) following the manufacturers protocol. 
Furthermore, 3 stop codons were added after the start codon to prevent translation utilizing 
primers as shown in Table 4.1 using the QuickChange II Mutagenesis Kit (Agilent 
Technologies) following the manufacturers protocol. High codon usage, Low codon usage, and 
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chimeric minigenomes were synthesized by Genscript (Piscataway, NJ) and cloned into the 
minigenome vector using the BamHI restriction enzyme sites.  
4.5.2 Minigenome Assay 
BSR-T7 cells (a gift from DR. Biao He, University of Georgia) were maintained in 
Dulbecco modified Eagle medium (DMEM) containing 5% fetal bovine serum (FBS) with 100 
units of penicillin and 20 U of streptomycin (221). Plasmids were then transfected into the cells 
in 60 mm plates after cells reached approximately 95% confluency. Briefly, cells were washed 
twice with Opti-MEM serum-free media (Invitrogen) and then transfected with 2 μg of pN-
minigenome, 1.5 μg of pN, 1 μg of pP, and 0.5 μg of pL using Lipofectamine 2000 (Invitrogen) 
(194). The cells were then incubated for 5 h at 37 °C and then fresh DMEM with 5% FBS was 
added. At 48 hpt, RNA was extracted from the cells using Trizol reagent (Ambion by Life 
Technologies) following the manufacturer’s protocol. Immediately after RNA isolation 1 μg of 
RNA was used for RT-PCR using SuperScript II Reverse Transcriptase (Invitrogen) according to 
the manufacturer’s protocol. The primers for RT-PCR were specific for mRNA, cRNA, and 
vRNA, as outlined in Table 4.2. Quantitative-PCR was performed on a QuantStudio 3 Real-
Time PCR System using the primers in Table 4.3 and the PowerUp Sybr Green Master Mix 
following the manufacturer’s protocol (Thermo Fisher Scientific). The data were analyzed by the 
2-ΔΔCT method as described previously (247). Furthermore, mock, template free, no RT-PCR, 
and the template only controls did not yield a CT value (data not included) after 40 cycles, 
indicating specific amplification of the selected genes (247). In addition, melting analysis 
revealed a single moiety for mRNA, cRNA, and vRNA for every minigenome vector. 
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4.5.3 Sequence Analysis 
Codon usage frequencies of the hosts (Table 4.4) were downloaded from GenScript 
Codon Usage Frequency Table Tool, and calculated for VSV genome using Sequence 
Manipulation Suite in bioinformatics.org. Changes in usage fraction were defined as significant 
if the difference was  ≥+ Δ0.14. Green indicates an increased fraction in NSV compared to 
human, whereas Red indicates a decreased fraction. Changes of nucleotides in VSV versus 
human codons are marked. For Lutzomyia longipalpis, fly codons are marked yellow if its 
fraction differs from that of VSV, or blue if it is the same as VSV (≤+Δ0.04) but differs from 
human. 
The Kappa Index of Coincidence was calculated as described previously, with the 
modification of plotting the X-axis as (A+G%) (256). All calculations were performed using 
Python (Python Software Foundation, version 3.5, https://www.python.org/) and the script is 
available at http://github.com/rgumpper/Biochemical_Tools . Data plots were drawn utilizing the 
open source plotting library for Python, Matplotlib (273). Sliding windows of 9, 18, 27, 36, 45, 
54, 63, 72, 81, and 90 were used for KIC calculations to examine the difference between local 
and global genome structure. A window size divisible by 9 was used as the nucleocapsid 
encapsidates 9 nucleotides per N subunit. 
4.5.4 Expression/Purification of NLP and Thermal Shift Assay (TSA) 
The NLPs were expressed and purified as previously described (144). Briefly, after initial 
NiNTA purification size exclusion was carried out with a HiLoad 16/100 Superdex 200 prep 
grade column equilibrated with 50 mM Tris pH 7.5 and 300 mM NaCl. The NLP was then 
reconstituted with either poly(rA) or poly(rU) purchased from Midland (Midland, TX) as shown 
previously (173). Excess RNA was removed by further size exclusion purification and RNA 
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composition was checked by 260/280 ratio on a UV-vis spectrophotometer. NLPs containing 
RNA from recombinant purification, poly(rA), or poly(rU) were then subjected to TSA as 
previously described (258). 
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Structural interactions between the RNA and Nucleoprotein. A. Ribbon representation of three 
Nucleocapsid protein subunits constructed from PDB 3PTX. Shown in red is the N-terminal arm, 
which interacts with adjacent subunits. Shown in blue and magenta are the N-lobe and the C-
lobe respectively. Shown in yellow is the C-terminal loop, which also interacts with adjacent 
subunits. Furthermore, the backbone of the RNA is shown as a tan line sandwiched between the 
N and C-lobes. B. A cartoon representation of a tight or loose interaction of the genomic RNA in 
the nucleocapsid. This would regulate the accessibility of the sequestered RNA to vRdRp and 
cause possible disassociation or stalling of vRdRp. C. Stick representation of nine nucleotides 
(Adenosine) encapsidated in the nucleocapsid. Shown in red are the first 4 nucleotides that have 
bases stacked with each other. Shown in blue, are nucleotides 5, 7, and 8 that also have bases 
stacked. Nucleotide 6 is shown in yellow and does not directly interact with other nucleotides.   
 
Figure 4.1 Structural interactions between the RNA and Nucleoprotein 
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In-situ assay of vRdRp activity. A. Vector for the minigenome based on the N gene of VSV. Under 
the control of the T7 promoter, the vector will express the vRNA copy of the N gene, flanked by 
the leader and trailer sequences. B. Top panel shows the relative fold decreases in RNA levels 
from all the minigenomes quantitated by in situ vRdRp activity assays. N stands for the wt 
genome, H stands for the high usage genome and L stands for the low usage genome. Bottom 
panel shows the fold increases of shortened RNAs using primers that correspond to the 
beginning of each viral RNA moiety, as ratios to the full length RNA moieties. C. Construction of 
the chimeric minigenomes. Each was constructed based on the golden-ratio with the darker 
color representing the wt genome and lighter gray representing high or low usage genomes. 
Each chimeric genome is shown in panel B as NH1 or NL1 etc. D. Highlighted sequence of the N 
gene showing the location of the high frequency codons, in green, or the low frequency codons in 
red. Furthermore, highlighted in cyan is the placement of 3-stop codons to prevent translation of 
the mRNA transcripts. Also shown, in magenta, is the PCR-tag utilized in qPCR to identify 
mRNA transcripts transcribed only from the minigenome. 
 
 
 
 
Figure 4.2 In-situ assay of vRdRp activity.  
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Calculated (A+G%) vs KIC. Each panel is a different window size ranging from 9-90 as 
multiples of 9 due to the number of nucleotides in each N subunit. The wt genome is plotted in 
gray, the high usage genome is plotted in red, and the low usage genome is plotted in blue. The 
center of mass is plotted in their respective color for each panel, and all three centers of mass 
are plotted on the wt plot. 
 
Figure 4.3 Calculated (A+G%) vs KIC.  
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Thermal Shift Assays. Thermal shift assay was carried out on the randomly incorporated RNA in 
the recombinantly expressed NLP, poly(rA), and poly(rU) in reconstituted NLPs. Sybr Safe, 
which monitors RNA thermo-release from the NLP, is shown in gray, while Sypro Orange, which 
monitors protein denaturation is shown in black. Average Tm’s with the standard deviation is 
shown on each panel. 
 
Figure 4.4 Thermal Shift Assays.  
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Table 4.1 Primers for Minigenome Construction 
 
 
 
 
 
 
 
 
 
 
 
 
Minigenome Construction 
N-gene-F 5'-CGTACGATGTGATGATGAGTCAAGAG-3' 
N-gene-R 5'-CGTACGTCATTTATCAAATTCTG-3' 
Triple Stop Codon-F 5-’GTAATCACGTACGATGTGATGATGAGTCAAGAGAATCATTG-3’  
Triple Stop Codon-R 5’ CAATGATTCTCTTGACTCATCATCACATCGTACGTGATTAC-3’ 
PCR-tag-F 5'-CGGATGGTTCGAAGATCAAAACAGAAAACCG-3' 
PCR-tag-R 5'-AGCCATTCAACCACATCTCTGCCTTGTGG-3' 
110 
 
 
 
 
 
 
 
 
Table 4.2 RT-PCR primers 
 
 
 
 
 
 
 
 
 
 
 
 
RT-PCR primers 
mRNA 5’-CCAGATCGTTCGAGTCGTTTTTTTTTTTTTTTTTCATTTGTCAAATTCTGACTTAG-3’ 
cRNA 5’-GCTAGCTTCAGCTAGGCATCCGCCGATATCTGTTAG-3’ 
vRNA 5’-GGCCGTCATGGTGGCGAATAGAAGTTTGGTAGGCTCG-3’ 
mRNA-short 5’-CCAGATCGTTCGAGTCGTTTGACATGTATGATTGATAC-3’ 
cRNA-short 5’-GCTAGCTTCAGCTAGGCATCCATCGTACGTGATTACTG-3' 
vRNA-short 5’-GGCCGTCATGGTGGCGAATCGTACGTGATTACTGTTAAAG-3’ 
β-Actin 5'-AGCACTGTGTTGGCGTACAG-3' 
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Table 4.3 Table of qPCR Primers 
 
 
 
 
 
qPCR Primers 
mRNA-F 5’-CCAGATCGTTCGAGTCGT -3’ 
mRNA-R 5’-AAGGCAGAGATGTGGTCG -3’ 
cRNA-F 5’-GCTAGCTTCAGCTAGGCATC-3’ 
cRNA-R 5’-AAACAGAAAACCGACTCCTG -3’ 
vRNA-F 5’-GGCCGTCATGGTGGCGAAT-3’ 
vRNA-R 5’-AGCAGGTTTGTTGTACGC -3’ 
mRNA-s-F 5’-CCAGATCGTTCGAGTCG-3’ 
mRNA-s-R 5’-ATGTGATGATGAGTC-3’ 
cRNA-s-F 5’-GCTAGCTTCAGCTAGGCATC-3’ 
cRNA-s-R 5’-ACGAAGACAAACAAACC-3’ 
vRNA-s-F 5’-GGCCGTCATGGTGGCGAAT-3’ 
vRNA-s-R 5’-ACGAAGACAAACAAAC-3’ 
β-Actin-F 5'-AGAGCTACGAGCTGCCTGAC-3' 
β-Actin-R 5'-AGCACTGTGTTGGCGTACAG-3' 
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Table 4.4 Fraction of Codon Usage 
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5 SUMMARY 
The goal of this work is to examine the basic structure-function relationships which guide 
viral replication via the nucleocapsid of VSV. Using a three-pronged approach towards 
understanding these basic principles, this work covers the discovery of a novel antiviral from an 
already widely understood class of compounds, the structure-based elucidation of a region 
important for viral polymerase assembly/processivity, and a paradigm shifting approach towards 
how the virus controls genetic drift of its genome.  
Utilizing these techniques, a new potential antiviral compound was discovered that 
specifically targets the genomic RNA in the nucleoprotein. In doing so, it can specifically inhibit 
the activity of the vRdRp. This is one of the first compounds that can directly target the 
sequestered viral RNA encapsidated by a nucleocapsid. This compound was also found to be 
non-toxic to cells at higher concentrations than is needed to inhibit the activity of the virus. With 
further iterations, the efficacy of this polyamide will only continue to improve. Furthermore, 
these principles can be directly applied to explore if other polyamides can target other NSVs, 
more specifically, pandemic diseases like RSV. The drawback to this approach is that this 
polyamide may be specific for VSV, seeing as it recognizes both the genome and the protein. 
However, this study opens the door for further investigations and design of polyamides that can 
target the nucleocapsid of other more pathogenic viruses. 
Our second approach, examines the fundamental interactions that guide the assembly and 
activity of the vRdRp. Through doing mutational studies on what we are calling the “access 
gate”, which is a helix positioned to protect the RNA, three key interactions were found. Three 
mutations E169A, F171A, and L174A were found to abolish the activity of the polymerase 
complex in a minigenome assay. Furthermore, incorporating these mutations into the 
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nucleoprotein does not disrupt the overall structure and assembly of the nucleocapsid. This 
would be an indicator that these interactions directly influence either the activity or the assembly 
of the vRdRp complex. Finally, after introducing these mutations into the viral genome and 
passaging the virus multiple times, we found compensatory mutations which restored the activity 
of the vRdRp. All the compensatory mutations that were found are on proteins associated with 
the polymerase complex. This indicates that these residues are crucial for the formation of an 
active vRdRp. With this information, we can probe the interactions that are imperative for the 
vRdRp, allowing us to conclude that the “access gate” helix is important for viral RNA 
transcription. 
The last investigation reveals new insights into how NSVs control their genetic drift. 
Since RNA viruses are well known to have extremely high mutational rates, there must be 
constraints in place for these viruses to control genetic drift. Traditionally the main evolutionary 
bottleneck was thought to be controlled by the host’s CUB, as in positive strand RNA viruses. 
However, this is not necessarily true when examining NSVs. This work has showed that the 
interactions between the genome and the nucleocapsid play a vital role in controlling the 
processivity of vRdRp. In turn, this would control genetic drift of the virus. Since the polymerase 
must access the RNA sequestered in the nucleocapsid, this would mean that the interactions 
between the genome and the nucleocapsid are central in controlling viral RNA transcription. The 
model states that there are some sections of the genome which will interact tightly with the 
nucleocapsid, making it harder for the polymerase to access and perhaps stalling/slowing it 
down. The inverse could also be true, loosely interacting sequences will make it too easy for 
polymerase to access the RNA and perhaps cause the complex to disassociate. Using an in situ 
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minigenome experiment, genomic sequence analysis, and stability assays, it was found that the 
pyrimidine/purine ratio plays a significant role in controlling the processivity of the vRdRp. 
All this data garners interesting insights into how the nucleocapsid is a central role in the 
life cycle of VSV. Since the nucleoprotein encapsidates the genome, the structure-function 
properties that control its access are vital to the understanding of the viral replication life cycle. 
Furthermore, since these aspects are ubiquitous across NSVs these studies could be directly 
applied to more pathogenic viruses. As shown in this dissertation, understanding how this viral 
family controls and protects its genomic material is important not only for basic science, but also 
for the development of antivirals and vaccines. Hopefully this dissertation can shed light on 
some of these fundamental interests when studying NSV virology, and hopefully have a small 
impact on humanity at large.    
5.1 Forward Looking Directions 
Part of science is utilizing the data available to ask pertinent questions. In pushing the 
boundaries of known knowledge, it is important to be constantly innovating with a clear plan on 
how to move projects forward. In the context of the antiviral drug discovery portion of this 
dissertation, polyamides represent a promising class of compounds. UMSL1011 is the first 
compound which has been found to target the genomic RNA in an NSV. It represents an 
auspicious start towards using these compounds to target more pathogenic NSVs like RSV, 
Ebola, and even Influenza. Currently, UMSL1011 is specific for VSV and needs to be drastically 
improved. Verifying the nucleotide sequence that UMSL1011 targets would allow for the 
development of a set of rules which could be ubiquitously applied to other NSVs. Also, a 
targeted genomic approach can allow for functional studies which elucidate sensitive parts of the 
VSV genome. To make a more efficacious polyamide, without knowing the sequence that it 
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targets, one approach is to focus on a compound which interacts with Arg312 and Gln318. 
Getting a compound to bind in the pocket close to the RNA could disrupt the pertinent 
interactions involved in viral transcription. Another approach is to shorten the polyamide. The 
crystal structure does not contain the full-length polyamide. While it is impossible to tell whether 
this is due to an unstructured portion of the compound in the structure, or if the compound is 
getting hydrolyzed, shortening the polyamide may lead to a targeted effect. One could try the 
structured portion of the polyamide found in the crystal or design one with five linkers to target 
the RNA base stacking. This may lead to a stable compound able to target VSVs genome. Of 
course, the drawback would be an increase in off-target effects, as the promiscuity of the 
compound is going to increase as it gets shorter. 
Studying the interactions which facilitate the assembly of the vRdRp has proven to be a 
challenging problem. The compensatory mutations identified in Chapter 3 lead to many 
interesting insights. Two of the mutations found on the L-protein are located on a single helix 
which borders the site where the template strand of RNA would enter for transcription to take 
place. One method to investigate if this region is important for producing an active vRdRp 
complex, is to identify all the solvent accessible residues on this helix and do alanine scanning 
mutations. Activity can then be tested by one of the in situ minigenome assays presented 
throughout this work. While this study would not allow one to identify if this helix is directly 
interacting with the nucleocapsid, it would build a stronger case for the access gate hypothesis. 
To directly test if this helix is interacting with the nucleocapsid, the construction of a fusion 
protein could be done. Replacing the N-terminal arm on the nucleocapsid with a flexible linker 
and the L-protein helix could allow one to recombinantly express a pseudo-vRdRp complex. 
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Structurally characterizing the fusion protein would be hard, but if in situ minigenome 
experiments show promising results, the likelihood of the fusion protein working would be high. 
Being able to understand the constraints placed on the vRdRp and how it influences the 
mutation rates of NSVs is an interesting topic of study. While VSV is a great model system, 
replicating these results with an Ebola or RSV minigenome system would give credence to this 
ubiquitous method of evolutionary control throughout all NSVs. Furthermore, identifying the 
impact that this may have on different genes in VSV would be interesting. While it has already 
been shown that changing the codons in the L-protein can lead to viral attenuation, other genes 
have yet to be investigated in this manner. Further quantifying the amount of short terminating 
transcripts by the polymerase when altering the base stacking properties, is another direction that 
this study to go. Being able to tell where the polymerase would be stalling/dissociating would 
give a better idea of sequences that the polymerase is sensitive too. Finally, an interesting 
approach to understand how sequences control mutational constraints of the polymerase may lie 
in the fast-developing field of Deep Learning. Neural networks are now being extensively used 
in natural language processing. Nucleotide sequences are nothing but a language which we are 
not fluent in. Utilizing the large databases of viral sequences, which are tied to activity or 
attenuation of the virus and applying what we have found about the base stacking properties to 
these sequences, it is possible to build a deep learning model which could reveal unforeseen 
patterns and predict attenuating mutants. 
While these are just some future directions that this work could take, sometimes the best 
scientific discoveries lie in the unpredictable. Most of the time an experiment does not tell you 
what you want, but it always tells you what is true. Following the truth will lead to interesting 
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discoveries and breakthrough scientific innovations. Nature always reveals herself in due time, it 
just takes a person who is willing to look and ask the right questions.   
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APPENDICES  
Appendix A 
Appendix A.1 
 2-ΔΔCT Values for Minigenome 
Comparison: 2-ΔΔCT 
UMSL1011:DMSO(control) 0.33 
DMSO(control):Mock(control) 0.88 
UMSL1011:Mock(control) 0.29 
 
Appendix A.2 
 
 
 
 
 
 
 
 
 
 
Figure A.2 Amplification plots of the qPCR in the minigenome assays in Figure 3.6. This 
illustrates that the controls do not have any amplification even when compared to the experimental 
conditions. 
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Appendix A.3 
Polyamide Characterization 
UMSL1013 Im-Py-Py-Py--Py-Py-Im-Py--Dp (3 TFA): 
1H NMR (600 MHz, DMSO-d6) being obtained now.  
HRMS (ESI) calculated for C58H71N21O10 [MH]
+, 1221.5684, found, 1221.5702. 
Reverse Phase HPLC purity (trace shown): 94%. 
 
UMSL2082 Im-Im-Py--Py-Py-Py--Ta (4 TFA): 
1H NMR (600 MHz, DMSO-d6)  = 7.54 (s, 1 H), 7.42 (s, 1 H), 7.20 -7.18 (dd, 1 H), 7.13 
(s, 1 H), 7.07 (d, 1 H), 7.01 (s, 1 H), 6.96 (d, 1 H), 6.85-6.84 (m, 2 H), 3.98-3.97 (m, 7 H), 3.80-
3.77 (m, 14 H), 3.48 (19 H, H2O), 3.37-3.35 (m, 3 H), 3.20-2.99 (m, 12 H), 2.84-2.81 (m, 3 H), 
2.73-2.71 (s, 4 H), 2.35-2.32 (t, 2 H), 2.27-2.25 (t, 2 H), 1.90-1.86 (m, 3 H), 1.79-1.73 (m, 5 H). 
HRMS (ESI) calculated for C48H64N18O8 [M]
+, 1020.5154, found, 1020.5101. 
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Reverse Phase HPLC purity (trace shown): 98%. 
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